Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
1/86  
 
 
 
CLINICAL INVESTIGATION PLAN  
(PROTOCOL ) 
 
 
PRODUCT:  Gelesis100  
 
 
TITLE:  A Randomized, Double -Blind, Placebo -Controlled, Parallel -Group 
Study Assessing the Effect of Gelesis100  on Body Weight in Overweight 
and Obese Subjects  with and without Type 2 Diabetes  
 
STUDY NAME: GLOW (Gelesis Loss Of Weight)  
 
 
 
 
 
 
PROTOCOL NUMBER:  G-04 
 
VERSION:  5.0 (Post -Amendment 4) 
 
VERSION DATE:  August 24, 2016 (Final)  
 
 
 
 
 
 
 
Not For Distribution – Do Not Copy  
This document is confidential and is to be distributed for review only to 
investigators, study staff, and applicable independent ethics committees or 
institutional review boards. The contents of this document shall not be disclosed to 
others wi thout written authorization from Gelesis, Srl., unless it is necessary to 
obtain informed consent from potential study participants.  
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
2/86  
SPONSOR /MANUFACTURER  Name: Gelesis, Srl.  
 
Address: Via Verdi , 188 
73021  Calimera (LE)  
Italy 
 
Phone: +39 0832 872 749  
Fax: +39 0802 121 708  
Signature  (Yishai Zohar) :  
 
 
 
 
SPONSOR’S TRIAL 
MONITOR  Name: Hassan M. Heshmati, M.D.  
 
Address: Gelesis, Srl.  
501 Boylston Street, Suite 6102  
Boston, MA 02116  
USA  
 
Phone: +1 215 275 -1275  
Fax: +1 617 249 -1570  
E-mail: hheshmati@gelesis.com  
Signature:  
                 
 
 
EMERGENCY CONTACT  Name: Hassan M. Heshmati, M.D.  
 
Address: Gelesis, Srl.  
501 Boylston Street, Suite 6102  
Boston, MA 02116  
USA  
 
Phone: +1 215 275 -1275  
Fax: +1 617 249 -1570  
E-mail: hheshmati@gelesis.com  
 
  

Protocol Number: G-04 (Version: 5.0; Version Date: August 24, 2016) Gelesis, Srl. 
Product: Gelesis100 
______________________________________________________________________________ 
Property of Gelesis, Srl. – Strictly Confidential 
 
3/86 PRINCIPAL /COORDINATING  
INVESTIGATOR  
 
EMERGENCY CONTACT 
BACKUP  Name: Frank L. Greenway , M.D.  
 
Address: Pennington Biomedical Research 
Center  
6400 Perkins Road  
Baton  Rouge, LA 70808  
USA  
 
Phone: +1 225 763-2578  
Fax: +1 225 763-3022  
E-mail: frank.greenway@pbrc.edu  
Signature:  
 
 
 
 
  

Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
4/86  
CHANGES  
 
Replacement:  
- Page 3 (Principal/Coordinator Investigator)  
 
Addition:  
- Section 1 ( Body weight criteria, Interim analysis)  
- Section 2 (Serum amylase, Genomic tests , Procedures for  extension study)  
- Section 4 ( AMY1, BDNF, CAPN10, CP, FTO, KCNJ11, LEPR, MC4R, NEGR1, 
NPC1, PCSK1, PPARG , SH2B1 , SLC16A13, TCF7L2 ) 
- Section 5.2 ( Details on h ydration of Gelesis100)  
- Section 7 ( Description of e xtens ion study)  
- Section 8.1 (Serum lipids)  
- Section 8.3 (Body weight criteria)  
- Section 11.3 (Physical activity)  
- Section 11.3.2.1 ( Serum amylase, Genomic  tests) 
- Section 12.1 (Scheduling of Visit 2 and Visit 13)  
- Section 12.2.1 ( Serum amylase, Genomic tests ) 
- Section 12.2.12 (Informed consent related to extension study)  
- Section 12.2.13 (Randomization related to extension study, Visit status related to 
extension study)  
- Section 15.5.4 (Interim analysis , Management of SADE ) 
- Section 15.5.4.1 (Unblinding  for interim  analysis ) 
- Section 15.5.4.2 ( Unblinding for m anagement of SADE)  
- Section 15.6 (Interim analysis)  
- Section 15 .7.5 ( Serum amylase, Genomic tests ) 
- Section 26 (References)  
 
Deletion:  
- Section 4 ( Ltd., s.r.o.)  
- Section 8.2 (Competitive enrollment)  
- Section 9.2.1 (Me dication for chronic disease)  
 
Clarification and Optimization:  
- Section 9.1 (11 mg)  
- Section 11.3.1.7 (Mild binge eater)  
- Section 13.1.3 (Health Canada)  
- Section 13.3.2 (Health Canada)  
- Section 14.2.1 ( Stopping rules, Interim analysis ) 
- Section 15.3 (Study endpoints)  
- Section 15.4 ( Sample size determination ) 
- Section 15.7 ( Statistics)  
- Section 15.7.1.1 (ITT population)  
- Section 15.8 (Statistics)  
- Section 15.8.6.1 (Study endpoints)  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
5/86 - Section 15.8.6.3 (Statistics)  
- Section 17.2 (Informed Consent Form)  
- Section 18.7 (Financial arrangements)  
- Section 20 (Protocol deviations)  
- Section 25 (Audit by Sponsor)  
 
Correction:  
- Section 9.1.9 (Detailed)  
- Section 15.7.3 (Biased)  
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
6/86  
TABLE OF CONTENTS  
 
1. CLINICAL TRIAL SU MMARY  ................................ ................................ ..............  11 
2. STUDY FLOW CHART  ................................ ................................ ............................  18 
3. CLINICAL INVESTIG ATION PLAN APPROVAL  ................................ ..............  19 
4. ABBREVIATIONS  ................................ ................................ ................................ ..... 20 
5. INTRODUCTION AND RATIONALE  ................................ ................................ .... 22 
5.1 Disease Background  ................................ ................................ ................................ .............................. 22 
5.2 Investigational Product  ................................ ................................ ................................ ......................... 23 
5.2.1 Clinical Data  ................................ ................................ ................................ ................................ ....24 
5.3 Rationale ................................ ................................ ................................ ................................ ................. 30 
6. OBJECTIVES  ................................ ................................ ................................ .............  30 
6.1 Primary ................................ ................................ ................................ ................................ ................... 31 
6.2 Secondary  ................................ ................................ ................................ ................................ ............... 31 
7. DESIGN  ................................ ................................ ................................ .......................  31 
8. POPULATION  ................................ ................................ ................................ ............  31 
8.1 Number of Subjects  ................................ ................................ ................................ ............................... 32 
8.2 Countries and Sites  ................................ ................................ ................................ ................................ 32 
8.3 Inclusion Criteria ................................ ................................ ................................ ................................ ...32 
8.4 Exclusion Criteria  ................................ ................................ ................................ ................................ ..33 
9. TREATMENT  ................................ ................................ ................................ .............  34 
9.1 Investigational Product  ................................ ................................ ................................ ......................... 34 
9.1.1 Selection of Gelesis100 Amount  ................................ ................................ ................................ .....35 
9.1.2 Selection of Placebo  ................................ ................................ ................................ ........................ 35 
9.1.3 Packaging and Labeling  ................................ ................................ ................................ ................... 35 
9.1.4 Responsibilities  ................................ ................................ ................................ ................................ 35 
9.1.5 Storage Conditions  ................................ ................................ ................................ ........................... 36 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
7/86 9.1.6 Administration Method  ................................ ................................ ................................ .................... 36 
9.1.7 Treatment of Overdose  ................................ ................................ ................................ .................... 36 
9.1.8 Compliance Assessment  ................................ ................................ ................................ .................. 36 
9.1.9 Retrieval and/or Destruction  ................................ ................................ ................................ ............ 36 
9.2 Concomitant Medication  ................................ ................................ ................................ ....................... 37 
9.2.1 Prohibited Medication ................................ ................................ ................................ ...................... 37 
9.2.2 Permitted Medication  ................................ ................................ ................................ ....................... 37 
9.3. Diet and Life -Style Recommendations  ................................ ................................ ................................ 38 
9.3.1 Diet  ................................ ................................ ................................ ................................ .................. 38 
9.3.2 Life -Style  ................................ ................................ ................................ ................................ ......... 38 
10. STUDY DURATION  ................................ ................................ ................................  39 
10.1 Study  Duration per Subject  ................................ ................................ ................................ ................ 39 
10.1.1 Screening Period  ................................ ................................ ................................ ............................ 39 
10.1.2 Baseline Period  ................................ ................................ ................................ .............................. 39 
10.1.3  Treatment Period  ................................ ................................ ................................ ........................... 39 
10.1.4 Post -Treatment Follow -up Period  ................................ ................................ ................................ ..39 
10.2. Total Study Duration  ................................ ................................ ................................ ......................... 39 
11. STUDY ENDPOINTS  ................................ ................................ ...............................  39 
11.1 Effectiveness Endpoints  ................................ ................................ ................................ ...................... 39 
11.1.1 Co -Primary Endpoints  ................................ ................................ ................................ ................... 39 
11.1.2 Secondary Endpoints  ................................ ................................ ................................ ..................... 40 
11.1.3 Tertiary Endpoints  ................................ ................................ ................................ ......................... 40 
11.2 Safety Endpoints  ................................ ................................ ................................ ................................ ..40 
11.2.1 Adverse Events  ................................ ................................ ................................ .............................. 40 
11.2.2 Physical Examination  ................................ ................................ ................................ .................... 40 
11.2.3 Vital Signs  ................................ ................................ ................................ ................................ .....41 
11.2.4 Laboratory Tests  ................................ ................................ ................................ ............................ 41 
11.3 Assessment Methods  ................................ ................................ ................................ ............................ 41 
11.3.1 Clinical  ................................ ................................ ................................ ................................ ........... 41 
11.3.2 Biological  ................................ ................................ ................................ ................................ .......44 
12. VISITS  ................................ ................................ ................................ .......................  44 
12.1 Schedule  ................................ ................................ ................................ ................................ ................ 44 
12.2 Assessments  ................................ ................................ ................................ ................................ .......... 45 
12.2.1 Visit 1 (Screening Visit; Day -21 to -1) ................................ ................................ ......................... 45 
12.2.2 Visit 2 (Baseline Visit; Day 0)  ................................ ................................ ................................ .......45 
12.2.3 Visit 3 (First Double -Blind Visit; Day 8 ± 2)  ................................ ................................ ................ 46 
12.2.4 Visit 4 (Second Double -Blind Visit; Day 15 ± 2)  ................................ ................................ .......... 46 
12.2.5 Visit 5 (Third Double -Blind Visit; Day 29 ± 2)  ................................ ................................ ............. 47 
12.2.6 Visit 6 (Fourth Double -Blind Visit; Day 43 ± 2)  ................................ ................................ ........... 47 
12.2.7 Visit 7 (Fifth Double -Blind Visit; Day 57 ± 2)  ................................ ................................ .............. 47 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
8/86 12.2.8 Visit 8 (Sixth Double -Blind Visit; Day 71 ± 2)  ................................ ................................ ............. 47 
12.2.9 Visit 9 (Seventh Double -Blind Visit; Day 85 ± 2)  ................................ ................................ ......... 48 
12.2.10 Visit 10 (Eighth Double -Blind Visit; Day 113  ± 3) ................................ ................................ .....48 
12.2.11 Visit 11 (Ninth Double -Blind Visit; Day 141 ± 3)  ................................ ................................ ......49 
12.2.12 Visit 12 (Tenth Double -Blind Visit; Day 169 ± 3)  ................................ ................................ ......49 
12.2.13 Visit 13 (First Follow -up Visit; Day 171; 2 days after Visit 12) (Last visit if entering extension 
study)  ................................ ................................ ................................ ................................ ........................ 49 
12.2.14 Visit 14 (Second Follow -up Visit; Day 197 ± 3)  ................................ ................................ ......... 50 
12.3 Definition of Source Data  ................................ ................................ ................................ .................... 50 
13. SAFETY MONITORIN G AND REPORTING  ................................ .....................  50 
13.1 Adverse Event and Device Deficiency  ................................ ................................ ................................ 50 
13.1.1 Investigational Product in this Clinica l Study  ................................ ................................ ................ 50 
13.1.2 Definitions  ................................ ................................ ................................ ................................ .....50 
13.1.3 Adverse Event and Device Deficiency Recording, Assessment, and Reporting Procedure  .......... 51 
13.1.4 Anticipated Adverse Device Effects  ................................ ................................ .............................. 52 
13.1.5 Risk Analysis  ................................ ................................ ................................ ................................ .53 
13.1.6 Precautions to Minimize Risk  ................................ ................................ ................................ ........ 53 
13.2 Pregnancy  ................................ ................................ ................................ ................................ ............. 53 
13.3 Responsibilities for Adverse Event and Pregnancy Reporting  ................................ ........................ 53 
13.3.1 Responsibilities of the Investigator  ................................ ................................ ................................ 53 
13.3.2 Responsibilities of the Sponsor  ................................ ................................ ................................ ......54 
14. TREATMENT/STUDY DISCONTINUATION  ................................ ....................  54 
14.1 Temporary Treatment Discontinuation ................................ ................................ ............................. 54 
14.2 Permanent Treatment/Study Discontinuation  ................................ ................................ .................. 54 
14.2.1 Reasons  ................................ ................................ ................................ ................................ .......... 54 
14.2.2 Procedures ................................ ................................ ................................ ................................ ......55 
15. STATIS TICAL CONSIDERATIONS  ................................ ................................ .... 55 
15.1 Treatment Arms  ................................ ................................ ................................ ................................ ..55 
15.2 Baseline and Visit Windows  ................................ ................................ ................................ ................ 56 
15.3 Description of Study Endpoints  ................................ ................................ ................................ .......... 56 
15.4 Sample Size Determination and Rationale  ................................ ................................ ........................ 56 
15.5 Randomization, Stratification, Blinding, and Unblinding  ................................ ............................... 57 
15.5.1 Randomization  ................................ ................................ ................................ ............................... 57 
15.5.2 Stratification  ................................ ................................ ................................ ................................ ..57 
15.5.3  Blinding  ................................ ................................ ................................ ................................ ......... 57 
15.5.4 Unblinding  ................................ ................................ ................................ ................................ .....58 
15.6 Interim Analysis ................................ ................................ ................................ ................................ ...59 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
9/86 15.6.1 Procedures for Interim Analysis  ................................ ................................ ................................ ....60 
15.6.2 Conditional Power Calculation  ................................ ................................ ................................ ......60 
15.6.3 Rule and Method for Increasing Sample Size  ................................ ................................ ................ 61 
15.6.4 Data Provided to Data Monitoring Committee  ................................ ................................ .............. 61 
15.6.5 Stopping Rule  ................................ ................................ ................................ ................................ 61 
15.6.6 Stopping Rule Provided to Sponsor by Data Monitoring Committee  ................................ ............ 61 
15.6.7 Type I Error Rate A djustment ................................ ................................ ................................ ........ 62 
15.7 General Statistical Considerations  ................................ ................................ ................................ .....62 
15.7.1 Analysis Populations ................................ ................................ ................................ ...................... 62 
15.7.2 Covariates  ................................ ................................ ................................ ................................ ......62 
15.7.3 Missing Data  ................................ ................................ ................................ ................................ ..62 
15.7.4 Multiple Comparisons and Multiplicity  ................................ ................................ ......................... 62 
15.7.5 Subgroup Analysis  ................................ ................................ ................................ ......................... 63 
15.8 Statistical Methods  ................................ ................................ ................................ .............................. 63 
15.8.1 Subject Disposition  ................................ ................................ ................................ ........................ 63 
15.8.2 Demographics and Baseline Characteristics Analysis  ................................ ................................ ...64 
15.8.3 Extent of Exposure to Study Product  ................................ ................................ ............................. 64 
15.8.4 Compliance with Diet, Life -Style, and Study Product  ................................ ................................ ...64 
15.8.5 Concomitant Medications/Therapies  ................................ ................................ ............................. 64 
15.8.6 Effectiveness Analysis  ................................ ................................ ................................ ................... 64 
15.8.7 Safety Assessments  ................................ ................................ ................................ ........................ 65 
16. STUDY COMMITTEES  ................................ ................................ ..........................  66 
16.1 Steering Committee  ................................ ................................ ................................ ............................. 66 
16.2 Data Monitoring Committee  ................................ ................................ ................................ ............... 66 
17. ETHICAL CONSIDER ATIONS  ................................ ................................ .............  66 
17.1 Principles  ................................ ................................ ................................ ................................ .............. 66 
17.2 Informed Consent  ................................ ................................ ................................ ................................ 66 
17.3 Ethics Committee/Institutional Review Board  ................................ ................................ .................. 67 
17.4 Confidentiality  ................................ ................................ ................................ ................................ .....67 
18. ADMINISTRATIVE A ND REGULATORY PROCED URES  .............................  67 
18.1 Laws  ................................ ................................ ................................ ................................ ...................... 67 
18.2 Clinical Trials Registration  ................................ ................................ ................................ ................. 68 
18.3 Curriculum Vitae  ................................ ................................ ................................ ................................ .68 
18.4 Record Retention  ................................ ................................ ................................ ................................ .68 
18.5 Data Protection  ................................ ................................ ................................ ................................ ....68 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
10/86 18.6 Insurance  ................................ ................................ ................................ ................................ .............. 68 
18.7 Financial Arrangements  ................................ ................................ ................................ ...................... 68 
19. CLINICAL INVESTI GATION PLAN AMENDMEN TS ................................ ..... 69 
20. CLINICAL INVESTI GATION PLAN DEVIATIO NS ................................ .........  69 
21. STUDY MONITORING  ................................ ................................ ..........................  69 
21.1 Responsibilities of the Sponsor  ................................ ................................ ................................ ........... 69 
21.2 Responsibilities of the Investigator  ................................ ................................ ................................ ....70 
22. PREMATURE DISCON TINUATION OF THE STU DY OR PREMATURE 
CLOSE -OUT OF A SITE  ................................ ................................ ..............................  70 
22.1 Decided by the Sponsor  ................................ ................................ ................................ ....................... 70 
22.2 Decided by the Investigator  ................................ ................................ ................................ ................ 70 
23. PROPERTY RIGHTS  ................................ ................................ ..............................  71 
24. COMMUNICATION AN D PUBLICATION OF RES ULTS  ...............................  71 
25. QUALITY ASSURANC E AUDITS AND REGULAT ORY INSPECTIONS  ..... 71 
26. REFERENCES  ................................ ................................ ................................ ..........  72 
27. APPENDICES  ................................ ................................ ................................ ...........  74 
27.1 Appendix 1: Binge Eating Disorder  ................................ ................................ ................................ ...75 
27.2 Appendix 2: Food Habits  ................................ ................................ ................................ .................... 79 
27.3 Appendix 3: Food Habits and Satisfaction  ................................ ................................ ........................ 81 
27.4 Appendix 4: Impact of Weight on Quality of Life  ................................ ................................ ............ 83 
27.5 Appendix 5: List of Source Data  ................................ ................................ ................................ ........ 86 
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
11/86 1. CLINICAL TRIAL SUMMARY  
 
TITLE  A randomized, double -blind, placebo -
controlled, parallel -group study assessing the 
effect  of Gelesis100  on body weight in 
overweight and obese subjects  with and 
without type 2 diabetes  
 
OBJECTIVES  Primary:  
- placebo-adjusted weight loss ≥ 3.0%  
- weight loss of at least 5% in ≥ 35% of 
subjects on Gelesis100  
 
Secondary:  
- decrease in serum insulin  
- decrease in insulin resistance ( homeosta sis 
model assessment -insulin resistance  
“HOMA -IR”) 
- decrease in plasma glucose  
- decrease in glycosylated hemoglobin  
(HbA1c ) 
- safety and tolerability  similar to placebo  or 
clinically acceptable  
 
DESIGN  Multicenter, randomized, double -blind, 
placebo -controlle d, parallel -group, fixed -
amount  
 
NUMBER OF SUBJECTS  Approximately 460 :  
- 230 subjects on Gelesis100  
- 230 subjects on placebo  
 
COUNTRIES AND SITES  US, Canada , and several Europ ean countries , 
approximately 38 sites 
 
INCLUSION CRITERIA  - male and female ambulatory subjects  (it is 
recommended to have at least 45 % of each 
gender ) 
- age ≥ 22 years and  65 years  
- body mass index (BMI) ≥ 27 and  40 (it is 
recommended to have  at least 70% of 
subjects  with BMI < 3 5 and body weight  
< 120 kg in at least 92% of all subjects ; 
subjects with BMI < 30 should have at least 
one comorbidity including untreated or 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
12/86 metformin -treated type 2 diabetes, untreated 
dyslipidemia with low -density lipoprotein 
(LDL) cholesterol ≥ 130 mg/dL (≥ 3.37 
mmol/L)  and/or triglycerides ≥ 150 mg/dL  
(≥ 1.69 mmol/L) or drug -treated 
dyslipidemia, and untreated hypertension 
with supine systolic blood pressure (SBP)  
≥ 140 mm Hg and/or supine diastolic blood 
pressure (DBP) ≥ 90 mm Hg based on the 
mean of two consecutive readings or drug -
treated hypertension ) 
- fasting plasma glucose ≥ 90 mg/dL and  
≤ 145 mg/dL (≥ 5.0 mmol/L and  
≤ 8.1 mmol/L) ; it is recommended to have 
approximately 45 to 55% non-diabetic 
normoglycemic subjects (fasting glucose ≥ 90 
mg/dL and < 100 mg/dL or ≥ 5.0 mmol/L and 
< 5.6 mmol/L)  and the rest , non-diabetic 
impaired fasting glucose subjects (fasting 
glucose ≥ 1 00 mg/dL and < 126 mg/dL or  
≥ 5.6 mmol/L and < 7.0 mmol/L) or  diabetic 
subjects either untreated (fasting glucose  
≥ 126 mg/dL and ≤ 145 mg/ dL or ≥ 7.0 
mmol/L and ≤ 8.1 mmol/L) or metformin -
treated ( metformin dose ≤ 1500 mg/day, 
fasting glucose ≤  145 mg/dL or ≤ 8.1 
mmol/L)  
- ability to follow verbal and written 
instructions  
- informed consent form signed by the 
subjects  
 
EXCLUSION CRITERIA  - pregnancy (or positive se rum or urine 
pregnancy test(s) in females of childbearing 
potential)  or lactation  
- absence of contraception in females of 
childbearing potential  
- history of allergic reaction to 
carboxymethylcellulose, citr ic acid, sodium 
stearyl  fumarate, raw cane sugar, gelatin , and 
titanium dioxide  
- administration of investigational products 
within 1 month prior to Screening Visit  
- subjects who stopped smoking within 6 
months prior to Screening Visit or 
considering smoking cessation during th e 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
13/86 study  
- subjects anticipating surgical intervention 
during the study  
- known type 1  diabetes  
- history of eating disorders including binge 
eating (except mild binge eater)  
- weight change > 3 kg within 3 months prior 
to and during the Screening period  
- supine SBP > 160 mm Hg and/or supine 
DBP  > 95 mm Hg  
- angina, coronary bypass, or myocardial 
infarction within 6 months prior to Screening 
Visit  
- history of swallowing disorders  
- esophageal anatomic abnormalities (e.g., 
webs, diverticuli, rings)  
- history of gastroesophageal reflux disease  
- history of gastric or duodenal ulcer  
- history of gastroparesis  (chronic nausea, 
vomiting, heartburn, …)  
- history of gastric bypass or any other gastric 
surgery  
- history of small bowel resection (except if 
related to appendectomy)  
- history of intestinal stricture (e.g., Crohn’s 
disease)  
- history of intestinal obstruction or subjects 
at high risk of intestinal obstruction  including 
suspected small bowel adhesions  
- history of abdominal radiation treatment  
- history of pancreatitis  
- history of malabsorption  
- history of sucrose intolerance  
- laxative users  
- history of hepatitis B or C  
- history of human immunodeficiency virus  
- history of cancer within the past 5 years 
(except adequately -treated localized basa l cell 
skin cancer or in situ  uterine cervical cancer)  
- any other clinically significant disease 
interfering with the assessments of 
Gelesis100  (e.g., disease requiring corrective 
treatment, potentially  leading to study 
discontinuation)  
- abnormal serum thyroid -stimulating 
hormone  (TSH)  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
14/86 - HbA1c > 8.5% (> 69 mmol/mol)  
- serum LDL  cholesterol  ≥ 190 mg/dL  
(≥ 4.93 mmol/L)  
- serum triglycerides ≥ 500 mg/dL  
(≥ 5.65 mmol/L)  
- positive test for drugs in the urine  
- any relevant biochemical abnormality 
interfering with the assessments of 
Gelesis100  
- anti-obesity medications (including herbal 
preparations) within 1 month prior to 
Screening Visit  
- antidiabetic medications within 1 month 
prior to Screening Visit (exc ept stable dose of  
metformin , ≤ 1500 mg/day, for at least 1 
month in subjects with type 2 diabetes)  
- systemic corticosteroids within 1 month 
prior to Screening Visit  
- thyroid hormones or preparations within 1 
month prior to Screening Visit (except stable  
dose of replacement therapy for at least 1 
month)  
- TSH suppression therapy for thyroid cancer  
- estrogen within 1 month prior to Screening 
Visit (except stable dose of replacement 
therapy for at least 1 month  or non -oral 
contraceptive for at least 3 mont hs) 
- any other medication or product known to 
cause weight loss or weight gain within 1 
month prior to Screening Visit  
- change in medications treating dyslipidemia 
within 1 month prior to Screening Visit  
(including change in dose)  
- change in medications  treating hypertension 
within 1 month prior to Screening Visit  
(including change in dose)  
- medications requiring mandatory 
administration with meal at lunch or dinner  
- anticipated requirement for use of 
prohibited concomitant medications  
 
INVESTIGATIONA L PRODUCT  Gelesis100  (medical device in capsule) and 
matching placebo  
 
TREATMENT ASSIGNMENT Gelesis100  (2.25 g) versus placebo, twice 
daily, before lunch and dinner  (20-30 min 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
15/86 AND ADMINISTRATION  before meal)  
 
Randomization ratio of 1:1  with 230 subjects 
per arm ( 2 arms)  
 
Stratification by country (or combination of 
countries), based on gender (male and 
female) , BMI at Screening Visit (< 35 and  
≥ 35), and fasting glucose status at Screening 
Visit ( normal  and impaired/diabetic ) 
 
Subjects to be treated in a  parallel -group 
design, for 24 weeks  
 
DIET AND LIFE -STYLE  - hypocaloric diet ( -300 kcal/day), meals to 
be consumed with water as instructed  
- moderate -intensity exercise  
- no change in smoking habits  
 
STUDY DURATION  PER 
SUBJECT  Screening period:  up to 3 weeks  
Baseline period:  1 day  
Treatment period:  24 weeks  
Post-treatment follow -up period:  4 weeks  
 
TOTAL  STUDY DURATION  Approximately 2 years (including 
approximately 1 and half years for 
enrollment)  
 
EFFECTIVENESS  ENDPOINTS  Co-primary:  
- body weight  
- body weight responders ( ≥ 5% weight loss ) 
 
Secondary:  
- plasma glucose status  
- plasma glucose  
- HOMA -IR 
- HbA1c  
- BMI  
 
Tertiary:  
- body weight responders ( ≥ 10% weight loss)  
- estimated excess body weight  
- body weight status  
- waist circumference  
- serum insulin  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
16/86 - serum C -reactive protein (CRP)  
- serum lipids  
- blood pressure  
- food intake  
- food habits  
- satisfaction  
- impact of weight on quality of life 
(IWQOL)  
 
SAFETY ENDPOINTS  - adverse events (AEs)  
- physical examination  
- vital signs  
- laboratory tests  
 
VISITS  Fourteen  visits including the Screening Visit  
 
STATISTICAL ANALYSIS  - this sample size of 460 randomized subjects 
(230 per arm) with an anticipated dropout rate 
of 30% (322 subjects completing the study, 
161 per arm) will allow e stablishing both 
super -superiority and superiority with 
sufficient statistical power  
- the sample size will provide 85% statistical 
power for a 3.0% margin super -superiority 
(i.e., delta of at least 4.5%) with a common 
SD of 5.0% and a type I error rate of  0.05 
(one-sided test)  
- the sample size will also provide at least  
90% statistical power to establish the 
superiority (difference between the two arms 
greater than 0)  with a common SD of 5.0% 
and a type I error rate of 0.05 ( two-sided  
tests)  
- study endpoints will be analyzed as percent 
change or change from baseline to Day s 169 
or 171 
- continuous parameters will be assessed by  
analysis of covariance  model  using the 
stratification factors and the respective 
baseline values for the endpoint  in the mod el 
- categorical parameters will be assessed by 
Logit model using the stratification factors 
and the respective baseline values for the 
endpoint  in the model  
- safety data will be summarized for each arm  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
17/86 - an interim analysis will be performed when 
approximately 50% of subjects have been 
randomized and completed Visit 13 (Week 
24) or early terminated , whichever comes 
first 
 
STUDY START DATE  Second  half of 201 4 
 
STUDY END  DATE  First half of 2017 
 
Protocol Number: G -04 (Version: 5.0; Ver sion Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
18/86 2. STUDY FLOW CHART  
 
Period  
(duration)  Screening  
( 21 days)  Baseline  
(1 day)  Double -blind treatment  
(168 days)  Follow -up 
(28 days)  
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13I 14 
Day -21 to -1 0 8 15 29 43 57 71 85 113 141 169 171 197 
Week  -3 to 0  0 1 2 4 6 8 10 12 16 20 24 25 28 
Informed  consent  X            XJ  
Demography, height  X              
Menopausal status, smoking status, m edical history  X              
Physical examination  X X       X    X  
Weight, waist circumference, vital signs (blood pressure, heart rate)  X X X X X X X X X X X X X X 
Dietary interview  X X X X X X X X X X X X X X 
Binge eating disorder  X              
Food habits before treatment   X             
Serum pregnancy testA X X       X    X  
Urine  pregnancy testA, serum amylaseB, genomi c testsC  X             
Electrocardiogram, urine drug screen  X              
TSHD X        X      
Plasma glucose  X X X X X    X    X  
Serum insulin   X X X X    X    X  
IWQOLE  X           X  
Serum CRP , vitaminsF  X       X    X  
Serum albumin  X X  X X    X    X  
Hematology,  blood chemistry , HbA1c  X X       X    X  
Food intakeG  X   X  X  X X X X   
Food habits and satisfaction after treatment             X   
Concomitant medication recording, AEs recording  X X X X X X X X X X X X X X 
Randomization   X             
Gelesis100 /placebo accountability    X X X X X X X X X X   
Gelesis100 /placebo dispensedH  X X X X X X X X X X    
AFemales of childbearing potential only.  BAt any of the Visits 2, 3, 4, 5, 9, or 13 . CAt any of the Visits 2, 3, 4, 5, 9, or 13  (tests not mandatory) . DThe assessment of Week 12 is for subjects on replacement therapy 
with thyroid hormones or preparations only.  EAt selected sites . FAt selected sites (v itamins include vitamin A, vitamins B 1, B 2, B 6, B 9, and B 12, vitamin D, and vitamin E ). GFood diary on 2 consecutive weekdays 
and 1 weekend day before the visit. HAdministration begins on Day 1 and continues through Day 168, before lunch and dinner.  ILast visit if entering extension study.  JIf entering extension study.  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
19/86 3. CLINICAL INVESTIGATION PLAN  APPROV AL  
 
A Randomized, Double -Blind, Placebo -Controlled, Parallel -Group Study A ssessing the 
Effect  of Gelesis100  on Body Weight in Overweight and Obese S ubjects  with and 
without Type 2 Diabetes . 
 
I agree to the terms of this Clinical Investigation Plan. I will conduct the study according 
to the procedures specified herein, and according to principles  of Good Clinical P ractices, 
ISO 14155:2011, and local regulations and requirements.  
 
 
Investigator:  
 
 
Name: _________________________________________________  
 
 
Signature: ______________________________________________  
 
 
Date: __________________ _______________________________  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
20/86 4. ABBREVIATIONS  
 
ADE: adverse device effect  
AE: adverse event  
am: ante meridiem  
AMY1:  salivary amylase  
ANCOVA: analysis of covariance  
BDNF: brain -derived neurotrophic factor  
BMI: body mass index  
C: Celsius  
CAPN10: calpain -10 
CEE: Central and Eastern Europe  
cm: centimeter  
CMC: carboxymethylcellulose  
CP: conditional power  
CRF: case report fo rm 
CRO: Contract Research Organization  
CRP: C -reactive protein  
DBP: diastolic blood pressure  
dL: deciliter  
ECG: electrocardiogram  
EEA: European Economic Area  
e.g.: exempli gratia  
EN: European Norm  
F: Fahrenheit  
FDA: Food and Drug Administration  
fl: fluid  
FLOW: First Loss Of Weight  
FTO: fat mass and obesity associated  
g: gram  
GCP: Good Clinical Practices  
GED: general educational development  
GLOW: Gelesis Loss Of Weight  
h: hour  
HbA1c : glycosylated hemoglobin  
HDL: high -density lipoprotein  
HOMA -IR: homeostasis  model assessment -insulin resistance  
ICH: International Conference on Harmonisation  
i.e.: id est  
in: inch  
ISO: International Organization for Standardization  
ITT: intention -to-treat 
IWQOL: impact of weight on quality of life  
kcal: kilocalorie  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
21/86 KCNJ11: potassium voltage -gated channel subfamily J member 11  
kg: kilogram  
L: liter  
lb: pound  
LDL: low -density lipoprotein  
LEPR: leptin receptor  
MA: Massachusetts  
MC4R: melanocortin -4 receptor  
M.D.: Medical Doctor  
mg: milligram  
M.I.: middle initial  
min: minute  
mL: milliliter  
mm Hg: millimeters of mercury  
mmol: millimole  
mol: mole  
μU: microunit  
n: number  
NEGR1: neuronal growth regulator 1  
NPC1: Niemann -Pick disease, type C1  
oz: ounce  
PCSK1: proprotein convertase subtilisin/kexin type 1  
pH: power of hydrogen  
pm: post  meridiem  
PP: per protocol  
PPARG: peroxisome proliferator -activated receptor gamma  
QEWP -R: questionnaire on eating and weight patterns -revised  
SADE: serious adverse device effect  
SAE: serious adverse event  
SAP: Statistical Analysis Plan 
SAS: Statistical Analysis System  
SBP: systolic blood pressure  
SD: standard deviation  
SH2B1: SH2B adapter protein 1  
SLC16A13: solute carrier family 16 member 13  
Srl.: società a responsabilità limitata  
TCF7L2: transcription factor 7 -like 2  
TEAE: treatment -emergent adverse eve nt 
TSH: thyroid -stimulating hormone  
UADE: unanticipated adverse device effect  
USADE: unanticipated serious adverse device effect  
US: United States  
USA: United States of America  
WHO: World Health Organization  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
22/86 5. INTRODUCTION AND RATIONALE  
5.1 Disease Background  
Overweight (body mass index (BMI) ≥ 25 and < 30) and obesity (BMI ≥ 30) are 
becoming major health problems worldwide  (1). The overweight/obesity ep idemic was 
first noted in US  and then spread to other industrialized nations; it is now being seen  even 
in developing countries  (2). The World Health Organization (WHO) estimated that the 
worldwide prevalence of obesity has nearly doubled between 1980 and 2008. In 2008, 
approximately 500 million adults around the globe were obese and in 2014, this number 
reach ed 600 million.  
 
Overweight and obesity are responsible for increased morbidity and mortality ( 3). The 
comorbid conditions associated with overweight/obesity include cancer, coronary heart 
disease, delayed puberty, depression, disability, dysli pidemia, gallbladder disease, gout, 
hypertension, liver disease, osteoarthritis, respiratory dysfunction, sleep apnea, sexual 
impairment, social discrimination, type 2 diabetes, and other practical limitations and 
challenges . Weight loss  of at least 5 to 1 0% appears to lower the risk of many of these 
comorbidities ( 4). 
 
Overweight and o besity are chronic conditions  and this characteristic should be 
considered when facing  overweight  and obese individuals. Management  of overweight  
and obesity includes hypocal oric diet, exercise, behavior modification, device  (e.g., 
intragastric balloon) , drug, and surgery (bariatric surgery) (1, 5 , 6, 7 ). The therapeutic 
benefit of all currently available anti -obesity tools  is limited  by their marginal efficacy, 
variable toler ability and safety profiles , and poor compliance . 
 
The intragastric balloon is an intervention  designed to reduce stomach volume  (7), but 
there are conflicting data on sustained weight loss and no clear data indicating a decrease 
in mortality. Side effects  include balloon movement, nausea, vomiting, pain, and stomach 
ulceration.  
 
The results from bariatric surgery  suggest that limiting the functional volume of the 
stomach is an effective modality for the treatment of obesity ( 6). However, because of the 
risk of peri -operative complications  and the relatively high cost , bariatric surgery  is 
usually reserved for the severely obese subjects . 
 
A need exists for a product that is easy to use, safe, and effective at inducing weight loss. 
Interventions which act me chanically by occupying stomach volume, increasing the 
elastic modulus  and viscosity of the upper gastrointestinal content, and exten ding gastric 
emptying time, could potentially be very beneficial.  
 
A medical device  which induces satiety and decreases hunger could result in decreased 
caloric intake and weight loss. The advantage of such a medical device  is that it would 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
23/86 not require to drastically restrict food choices and would circumvent the challenge  of 
unacceptabl e hunger levels which has derailed so many dietary interventions in the past.  
 
5.2 Investigational  Product  
Gelesis100  is a novel, biocompatible  hydrogel, composed of carboxymethylcellulose 
(CMC) sodium salt (E466) cross -linked with citric acid  (E330) . More  than 99% of 
Gelesis100  consists of CMC and the rest is composed of citric acid. CMC and citric acid 
are safe food additives for use within the European Union  (European Directive 95/2/EC 
on Food Additives other than Colors and Sweeteners ) and are listed in the List of Dietary 
Supplement Ingredients in use before October 15, 1994  published by the National 
Nutritional Food Association. In the proposed study, Gelesis100  will be used as a 
medical device.  It is considered as a Class III device in Europe , a Class IV device in 
Canada,  and a non -significant risk device in US.  
 
Following ingestion of the Gelesis100  (capsule presentation), the capsule  disintegrate s in 
the stomach and re leases a hydrogel  which is capable of absorbing water solutions up to 
100 times its original weight in the gastrointestinal environment. The Gelesis100  device 
hydrates in the stomach and converts a volume of liquids into a volume of small, distinct 
gel particles. The hydrated gel particles mix homogenously with ingested foods, c reating 
a larger volume with a higher elasticity and viscosity  of the stomach and small intestine 
contents . For example, 2.25 g of Gelesis100  will create a volume of  approximately 225 
mL. The created volume does not exceed  the volume of liquid present, min imizing the 
risk of distension. The hydrati on rate of Gelesis100  in the different parts of the 
gastrointestinal tract has been demonstrated in vitro  (Figure 1 ). Variations in its hydration 
capacity are mainly related to variations of the pH and ionic strength of the external 
solutions. The transit time reported in Figure 1 is only an example. Transit time is 
affected by the meal size and content.  
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
24/86 Figure 1. Performance of Gelesis100  in simulated gastrointestinal conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By occupying the gastric and intestinal cavities and by increasing the elasticity and the 
viscosity of the ingested  foods, Gelesis100  induces satiety and reduces food intake, 
thereby contributing to weight reduction. Gelesis100  partially degrades in the large 
intestine and loses its three dimensional matrix structure and most of its  absorption 
capacity. The water is absorbed from the hydrogel back in the co lon and the device is 
expelled in the feces.  
 
All relevant information concerning Gelesis100  is available in the Investigator’s 
Brochure ( 8). This Clinical Investigation Plan  will summarize the available clinical data.  
 
5.2.1 Clinical Data  
5.2.1.1 Effect on Satiety and Hunger  
This study was aimed to assess the effects of a single administration of Gelesis100  on 
satiety and hunger ( 9). The study was conducted at the Agostino Gemelli Hospital, Rome, 
Italy. Ninety -five subjects were studied (Table 1). Study subjects received 2 g of 
Gelesis100  versus placebo before breakfast, lunch, and dinner, in a double -blind, cross -
over fashion. There was a 2-day washout  period between each administration of 
Gelesis100  for each subject. Meals consisted of habitual i ntake and were consumed at 
home. Satiety was assessed using a self -administered questionnaire immediately, and 30 
and 60 min after meal. The questionnaire included 5 options to score the feeling of 
satiety: not at all (score 0), a little (score 1), enough (score 2), very (score 3), and very 
much (score 4). Hunger was assessed using the same type of questionnaire before meal.  
 
Simulated gastrointestinal transit time (min)  
Hydration  ratio  (g/g)  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
25/86 Table 1. Clinical characteristics of the 95 study subjects.  
 
Gender (n ) Age (years)  BMI * 
Male  Female  Mean ± SD  Range  Mean ± SD  Range  
22 73 41 ± 12  19-67 31.1 ± 7.5  18.0-55.9 
*Twenty -one subjects had normal (or subnormal) BMI , 22 were overweight, and 52 were 
obese.  
 
Gelesis100  significantly increased the feeling of satiety at 30 min after breakfast and 
dinner (Table 2) and at 60 min after lunch and dinner (Table 3). 
 
Table 2. Satiety scores (mean ± SD) at 30 min post -meal.  
 
Meal  Gelesis100  Placebo  P value  
Breakfast  1.85 ± 0.93  1.63 ± 0.95  0.037  
Lunch  1.84  1.14 1.66  0.87 0.071  
Dinner  1.98  0.97 1.70  1.01 0.004  
 
 
Table 3. Satiety scores (mean ± SD) at 60 min post -meal.  
 
Meal  Gelesis100  Placebo  P value  
Breakfast  2.13 ± 1.00  2.12 ± 0.83  0.960  
Lunch  2.35  1.06 2.07  0.86 0.007  
Dinner  2.46  1.12 2.15  0.99 0.006  
 
The placebo -adjusted effect of Gelesis100  on satiety (first meal effect) is reported in 
Figure 2. 
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
26/86 Figure 2. Placebo -adjusted change in post-meal satiety scores (%) after Gelesis100  
administration . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The administration of Gelesis100  before lunch significantly decreased the feeling of 
hunger before the subsequent dinner (Table 4). 
 
Table 4. Hunger scores (mean ± SD) before lunch and dinner following 
Gelesis100 /Placebo administration before breakfast and  lunch, respectively.  
 
Time  Gelesis100  Placebo  P value  
Before lunch  1.71 ± 1.00  1.67 ± 0.83  0.702  
Before dinner  1.47 ± 1.16  1.77 ± 0.98  0.011  
 
The placebo -adjusted effect  of Gelesis100  on hunger (second meal effect) is reported in 
Figure 3. 
 
  
05101520
Breakfast Lunch Dinner30 min
60 min
*P < 0.05  
**P < 0.01  ** ** 
** * 
Percent  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
27/86 Figure 3. Placebo -adjusted change in pre-meal hunger score s (%) before lunch and 
dinner, after Gelesis100  administration before breakfast and lunch , respectively . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment with Gelesis100  was safe and well tolerated. Fifteen subjects (15.8%) reported 
at least 1 symptom during the study. No detailed information was recorded as to whether 
the symptoms occurred after the administration of Gelesis100  or placebo (or both). 
Gastrointestinal symp toms (solicited adverse events “ AEs”) were reported in 13 subjects 
(13.7%) during the study (Table 5). 
 
Table 5. Gastrointestinal symptoms during Gelesis100 /Placebo administration in 95 
subjects.  
 
Symptoms*  Number of subjects  Percentage of subjects  
Nausea  7 7.4 
Constipation  4 4.2 
Stomach ache  4 4.2 
Vomiting  1 1.1 
Diarrhea  1 1.1 
*No information was recorded as to whether the symptoms occurred after the 
administration of Gelesis100  or placebo.  
 
Three subjects (3.2%) reported more than 1 gastrointestinal symptom during the study: 2 
reported 2 symptoms (stomach ache and diarrhea, nausea and constipation) and 1 
reported 3 symptoms (nausea, vomiting, and stomach ache). Of the 7 subjects who 
-20-15-10-505
Lunch DinnerPre-meal
*P < 0.02  * 
Percent  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
28/86 reported nausea during the study, all had a medical history of at least 1 gastrointestinal 
disorder (esophagitis, epigastralgia, colitis, constipation, and proctitis). Non -
gastrointestinal symptoms (isolated headaches) were reported in 2 subjects (2.1%) during 
the study. No serious AE (SAE) was observed during the study.  
 
In conclusion, a single administration of Gelesis100  significantly increases the post -meal 
feeling of satiety in humans. The administration of Gelesis100  before lunch significantly 
decreases the fe eling of hunger before the subsequent dinner. The treatment is safe and 
well tolerated.  
 
5.2.1.2 Effect on Body Weight  
This study  (FLOW = First Loss Of Weight) was aimed to assess the effect of repeated 
administration of Gelesis100  on body weight  (10). The study was conducted at 5 sites in 
3 European countries ( Denmark , Czech Republic, and Italy). One hundred twenty -eight 
subjects were randomized  into 3 arms : Gelesis100  2.25 g , Gelesis100  3.75 g , or placebo . 
Subjects received 5 capsules of Gelesis100  or pla cebo before lunch and dinner, in a 
double -blind and  parallel -group fashion. A hypocaloric diet ( -600 kcal/day) was 
prescribed to all subjects. The duration of the treatment was 12 weeks. One hundred 
twenty five subjects had at least one post -baseline asses sment of body weight (intention -
to-treat “ITT” population). Forty -two of the ITT subjects were on Gelesis100  2.25 g , 41 
on Gelesis 100 3.75 g , and 42 on placebo  (Table 6) . One hundred ten subjects completed 
the key visit of the study at Day 87  for the asses sment of body weight . One hundred 
twenty -six subjects provided safety data.  The primary efficacy  endpoint was assessed by 
analysis of covariance (ANCOVA) model in the ITT population with baseline weight, 
gender, and BMI  status as covariates.  
 
Table 6. General  characteristics of the ITT population  at baseline . 
 
Parameter  Gelesis100  2.25 g   
(n = 42)  Gelesis100  3.75 g   
(n = 41)  Placebo  
(n = 42)  
Male (n)  13 (31%)  14 (34%)  13 (31%)  
Female (n)  29 (69%)  27 (66%)  29 (69%)  
Age (years) * 42.4  12.3 46.1  11.2 44.0  11.7 
BMI * 31.2  2.3 31.8  2.5 32.0  2.3 
Overweight (n)  14 (33%) 12 (29%)  12 (29%)  
Obese (n)  28 (67%) 29 (71%)  30 (71%)  
Glucose (mg/dL) * 
Glucose (mmol/L) * 93  10 
5.18  0.54 94  9 
5.20  0.50 96  10 
5.31  0.58 
*Mean  SD. 
 
Body weight decreased significantly at Day 87  in subjects on Gelesis100 2.25 g  with a 
placebo -adjusted weight loss of 2.0% and a total body weight loss of 6.1% (Table 7).  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
29/86 Table 7 . Body weight (% change from baseline) at Day 87  in the ITT population . 
 
Arm  Number of subjects  Mean ± SD  P value   
(versus placebo)  
Gelesis100 2.25 g  42 -6.1  5.1 0.026 
Gelesis100 3.75 g  41 -4.5  4.5 0.859 
Placebo  42 -4.1 ± 4.4 - 
 
Subjects on Gelesis100 2.25 g  had higher rate of weight loss ≥ 10% and lower rate of 
weight gain (Table 8). Lower tolerability and compliance may explain the observed 
efficacy result with Gelesis100 3.75 g . 
 
Table 8 . Body weight response at Day 87  in the ITT population . 
 
Parameter  Gelesis100  2.25 g   
(n = 42)  Gelesis100  3.75 g   
(n = 41)  Placebo  
(n = 42)  
Weight gain  3 (7%)  9 (22%)  7 (17%)  
Weight loss < 5%  21 (50%)  13 (32%)  18 (43%)  
Weight loss ≥ 5%  18 (43%)  19 (46%)  17 (40%)  
Weight loss ≥ 10%  11 (26%)  5 (12%)  5 (12%)  
 
The extent of weight loss at Day 87 was more pronounced in subjects on Gelesis100   
2.25 g with impaired fasting glucose at baseline . The placebo -adjusted weight loss was 
5.3% and the total body weight loss was 10.9%  (Table 9). There was a significant 
negative correlation between fasting glucose at baseline and change in body weight at 
Day 87 in subjects on Gelesis100 2.25 g  (r = -0.50; P < 0.001)  contrasting  with a lack of 
significant correlation in Gelesis100 3.75 g  arm (r = -0.01; P = 0.968) and placebo arm  
(r = -0.06; P = 0.708) . 
 
Table 9 . Body weight (% change from baseline) at Day 87  in the ITT population in 
subjects with impaired fasting glucose at baseline . 
 
Arm  Number of subjects  Mean ± SD  P value   
(versus placebo)  
Gelesis100  2.25 g  9 -10.9  4.3 0.019 
Gelesis100  3.75 g  9 -4.2  5.7 0.348 
Placebo  11 -5.6 ± 4.8 - 
 
Treatment with Gelesis100  was safe and well tolerated. Thirty -one subjects ( 74%) on 
Gelesis100  2.25 g , 35 subjects (85%) on Gelesis100  3.75 g , and 36  subjects (84%) on 
placebo  reported at least 1 AE during the study  (mainly gastrointestinal AEs) . Bloating, 
flatulence, abdominal pain, and diarrhea  were the most common  gastrointestinal AEs 
with lower prevalence in Gelesis100 2.25 g  compared to placebo and Gelesis100  3.75 g  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
30/86 arms  (Table 10) . Common cold and headache were t he most comm on non -
gastrointestinal AEs. S AEs were  observed in 3 subjects on placebo (gallstone and 
abdominal pain). The AEs were usually of mild intensity, occurred  at different times 
during the course of the study, and resolved within 1 week in most cases . 
 
Table 10 . Gastrointestinal AEs* in the safety  population . 
 
Parameter  Gelesis100 2.25 g   
(n = 42)  Gelesis100 3.75 g   
(n = 41)  Placebo  
(n = 43)  
Any gastrointestinal  AE 25 (60%)  31 (76%)  32 (74%)  
Bloating ** 12 (29%)  15 (37%)  16 (37%)  
Flatulence ** 11 (26%)  15 (37%)  13 (30%)  
Abdominal pain ** 9 (21%)  12 (29%)  15 (35%)  
Diarrhea ** 8 (19%)  10 (24%)  16 (37%)  
*Gastrointestinal AEs were solicited and recorded through a questionnaire.  **Similar 
AEs are grouped under one main term.  
 
Dropout after randomization occurred in 2 subjects (5%) on Gelesis100 2.25 g, 10 
subjects (24%) on Gelesis100 3.75 g, and 9 subjects (21%) on placebo. No AE was 
responsible f or the dropout with Gelesis100 2.25 g.  
 
In conclusion, repeated administration of Gelesis100 (2.25 g twice daily)  over 12 weeks 
significantly decreases the body weight in overweight and obese subjects, especially in 
subjects with impaired fasting glucose at baseline . The treatment is safe and well 
tolerated.  
 
5.3 Rationale  
Gelesis100 increases the volume and elasticity of the stomach and small intestine 
contents, and thus, inducing satiety and reducing food intake.  Through its mechanical  and 
non-pharmacological  approach,  Gelesis100 , as a medical device, is a product that is well-
positioned to overcome the limitations of the current weight -loss tools and fulfill the 
overwhelming unmet medical need for a safe and effective weight -loss product in 
overweight and obese subjects, especially in those with impaired fasting glucose . 
 
6. OBJECTIVES  
This study has the following objectives:  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
31/86 6.1 Primary  
 To assess the decrease in  body weight after repeated administration  of Gelesis100  
over a period of 168 days in overweight and obese subjects  with and without type 
2 diabetes (“placebo -adjusted ” or “difference with placebo” weight loss ≥ 3.0%)  
 To assess the body weight loss of at least 5% after  repeated administration  of 
Gelesis100  over a period of 168 days in overweight and obese subjects  with and 
without type 2 diabetes (≥ 35% of subjects on Gelesis100 ) 
 
6.2 Secondary  
 To assess the decrease in  serum insulin  after repeated administration  of 
Gelesis100  over a period of 168 days in overweight and obese subjects  with and 
without type 2 diabetes  
 To assess the decrease in  insulin  resistance ( homeostasis model assessment -
insulin resistance “HOMA -IR”) after  repeated administration  of Gelesis100  over 
a period of 168 days in overweight and obese subjects  with and without type 2 
diabetes  
 To assess the decrease in  plasma glucose  after repeated administration  of 
Gelesis100  over a period of 168 days in overweight and obese subjects  with and 
without type 2 diabetes  
 To assess the decrease in  glycosylated hemoglobin  (HbA1c)  after repeated 
administration  of Gelesis100  over a period of 168 days in overweight and obese 
subjects  with and without type 2 diabetes  
 To demonstrate safety and tolerability similar to placebo  or clinically acceptable 
of repeated administration  of Gelesis100  over a period of 168 days in overweight 
and obese subjects  with an d without type 2 diabetes  
 
7. DESIGN  
This is a multicenter, randomized, double -blind, placebo -controlled, parallel -group, 
fixed -amount study using 1 amount of Gelesis100 . 
 
At the end of this study, an extension study will be proposed to all subjects who have 
completed 24 weeks of treatment and lost at least 3% of their body weight from baseline  
in order to  assess the effectiveness and safety  of Gelesis100 after an additional exposure 
of 24 weeks  on an open -label basis . 
 
8. POPULATION  
The population will include overweight and obese subjects  with and without type 2 
diabetes . 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
32/86 8.1 Number of Subjects  
Approximately 460 subjects will be randomized in this study (approximately 230 on 
active product  and 230 on placebo). The selection and enro llment of subjects through 
advertisement  is highly recommended . Subjects who once failed to meet the 
inclusion/exclusion criteria will not be re -screened  (except for fasting plasma glucose and 
serum lipids, upon approval from the Sponsor) . 
 
8.2 Countries and Sites  
The study will be conducted in US, Canada, and several European countries in 
approximately 38 sites.   
 
The lists of Advisors, Investigators, investigation sites , laboratories, and other parties  are 
reported in separate documents.  The Sponsor will  update  and maintain these lists and 
communicate  them  with the Clinical Study Report . 
 
8.3 Inclusion Criteria  
1. Male and female ambulatory subjects (it is recommended to have at least 45 % of 
each gender ) 
2. Age ≥ 22 years and  65 years  
3. BMI ≥ 27 and  40 (it is recommended to have  at least 70% of subjects with BMI 
< 35 and body weight < 120 kg in at least 92% of all subjects ; subjects with BMI 
< 30 should have at least one comorbidity including untreated or metformin -
treated type 2 diabetes, untreated dyslipidem ia with low -density lipoprotein 
(LDL)  cholesterol ≥ 130 mg/dL ( ≥ 3.37 mmol/L)  and/or triglycerides ≥ 150 
mg/dL ( ≥ 1.69 mmol/L)  or drug -treated dyslipidemia , and untreated hypertension  
with supine systolic blood pressure (SBP)  ≥ 140 mm Hg and/or supine diastolic 
blood pressure (DBP)  ≥ 90 mm Hg  based on the mean of two consecutive 
readings  or drug -treated hypertension ) 
4. Fasting plasma glucose ≥ 90 mg/dL and ≤ 145 mg/dL (≥ 5.0 mmol/L and  
≤ 8.1 mmol/L) ; it is recommended to have approximately 45 to 55% non -diabetic 
normoglycemic subjects ( fasting glucose ≥ 90 mg/dL and < 100 mg/dL or ≥ 5.0 
mmol/L and < 5.6 mmol/L) and the rest, non -diabetic  impaired fasting glucose 
subjects (fasting glucose ≥ 100 mg/dL and < 126 mg/dL or ≥ 5.6 mmol/L and < 
7.0 mmol/L) or diabetic subjects either : 
- untreated (fasting glucose ≥ 126 mg/dL and ≤ 145 mg/dL or ≥ 7.0 mmol/L and  
≤ 8.1 mmol/L)  
- or metformin -treated ( metformin dose ≤ 1500 mg/day, fasting glucose ≤ 145 
mg/dL or ≤ 8.1 mmol/L)  
5. Ability to follow verbal and  written instructions  
6. Informed Consent Form signed by the subjects  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
33/86 8.4 Exclusion Criteria  
1. Pregnancy (or p ositive serum or urine pregnancy test(s) in females of childbearing 
potential ) or lactation  
2. Absence of medically approved contraceptive methods in females of childbearing 
potential (e.g., hysterectomy, non-oral contraceptive medications or intrauterine 
device combined with a barrier method, two combined barrier methods such as 
diaphragm and condom or spermicide , or condom and spermicide ; bilateral t ubal 
ligation and vasectomy are not acceptable contraceptive methods)  
3. History of allergic reaction to CMC , citr ic acid, sodium stearyl fumarate, raw 
cane sugar, gelatin, and titanium dioxide  
4. Administration of investigational products within 1 month prior t o Screening Visit  
5. Subjects who stopped smoking within 6 months prior to Screening Visit or 
considering smoking cessation during the study  
6. Subjects anticipating surgical intervention during the study  
7. Known type 1 diabetes  
8. History of eating disorders including binge eating  (except mild binge eater)  
9. Weight change > 3 kg within 3 months prior to and during the Screening period  
10. Supine SBP > 160 mm Hg and/or supine DBP  > 95 mm Hg  (mean of two 
consecutive readings ) 
11. Angina, corona ry bypass, or myocardial infarction within 6 months prior to 
Screening Visit  
12. History of swallowing disorders  
13. Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings)  
14. History of gastroesophageal reflux disease  
15. History of gastric or duodenal ulcer  
16. History of gastroparesis  (chronic nausea, vomiting, heartburn, …)  
17. History of gastric bypass or any other gastric surgery  
18. History of small bowel resection (except if related to appendectomy)  
19. History of intestinal stricture (e.g., Crohn’s disease)  
20. History of  intestinal obstruction or subjects at high risk of intestinal obstruction  
including suspected small bowel adhesions  
21. History of abdominal radiation treatment  
22. History of pancreatitis  
23. History of malabsorption  
24. History of sucrose intolerance  
25. Laxative users  
26. History of hepatitis B or C  
27. History of human immunodeficiency virus  
28. History of cancer within the past 5 years (except adequately -treated localized 
basal cell skin cancer or in situ  uterine cervical cancer)  
29. Any other clinically significant disease interfering with the assessments of 
Gelesis100 , according to the Investigator  (e.g., disease requiring corrective 
treatment, potentially  leading to study discontinuation)  
30. Abnormal serum thyroid -stimulating hormone  (TSH)  
31. HbA1c > 8.5% (> 69 mmol/mol)  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
34/86 32. Serum low -density lipoprotein cholesterol  ≥ 190 mg/dL ( ≥ 4.93 mmol/L)  
33. Serum triglycerides ≥ 500 mg/dL ( ≥ 5.65 mmol/L)  
34. Positive test for drugs in the urine  
35. Any relevant biochemical abnormality interfering with the assessments o f 
Gelesis100 , according to the Investigator  
36. Anti-obesity medications (including herbal preparations) within 1 month prior to 
Screening Visit  
37. Antidiabetic medications within 1 month prior to Screening Visit ( except stable 
dose of metformin, ≤ 1500 mg/day, for at least 1 month in subjects with type 2 
diabetes)  
38. Systemic corticosteroids within 1 month prior to Screening Visit  
39. Thyroid hormones or preparations within 1 month prior to Screening Visit (except 
stable dose of replacement therapy for at least 1 month)  
40. TSH suppression therapy for thyroid cancer  
41. Estrogen within 1 month prior to Screening Visit (except stable dose of 
replacement therapy for at least 1 month  or non -oral contraceptive for at least 3 
months ) 
42. Any other medication or product known to cause weight loss or weight gain 
within 1 month prior to Screening Visit  
43. Change in m edications treating dyslipidemia within 1 month prior to Screening 
Visit  (including change in dose)  
44. Change in m edications treating hypertension within 1 month prior to Screening 
Visit  (including change in dose)  
45. Medications requiring mandatory administration with meal at lunch or dinner  
46. Anticipated requirement for use of prohibited concomitant medications (see 
Section 9.2.1)  
 
9. TREATMENT  
9.1 Investigational Product  
Gelesis100  (medical device  in capsule) and matching placebo will be used. Each capsule 
of Gelesis100  contain s approximately 750 mg of CMC  sodium salt cross -linked with 
citric acid , and 11 mg of sodium stearyl fumarate . Each capsule of placebo contain s 
approximately 900 mg of raw cane sugar ( sucrose ). 
 
The envelopes of Gelesis100 and placebo capsules are provided by Capsugel. They each 
contain 126 mg of gelatin and 4 mg of titanium dioxide. The gelatin component is an 
animal -derived product. According to Capsugel , the gelatin undergoes stringent 
preliminary physical, chemical, and microbiological tests before it is released into 
production by the Capsugel quality control department.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
35/86 9.1.1 Selection  of Gelesis100  Amount  
Since Gelesis100  hydrates  approximately 100 times its weight in the gastrointestinal 
tract, the proposed amount of 2.25 g of Gelesis100  (3 capsules before lunch and dinner ) 
will expose the subjects to a volume of approximately 225 mL. This is well below the 
estimated volume of the human stomach which is about 900 mL ( 11) but is similar to  the 
amount used in the FLOW  study showing significant decrease in body weight  and a good 
safety profile . 
 
9.1.2 Selection  of Placebo  
To minimize the risk of  unblinding in case the capsules are open ed accidentally or 
intentionally , raw cane sugar was selected as placebo since it has the same color and 
shape as Gelesis100 . Raw cane sugar contains sucrose (simple carbohydrate). The daily 
amount of sucrose  (< 6 g/day) administered through placebo capsules is clinically 
acceptable (12) and has no  significant health impact  (including in diabetic subjects) , 
especially if the subjects are following the dietary recommendations  of the study . Indeed, 
substantial evidence from clinical st udies demonstrates that dietary sucrose does not 
increase glycemia more than isocaloric amounts of starch  (13). 
 
9.1.3 Packaging and Labeling  
The study product will be packaged in polypropylene bottles  (3 capsules per b ottle) and 
the bottles will be packaged in weekly boxes . Each weekly box will contain allowance 
for 1 additional day  of dosing (i.e., 2 x 3  additional capsules) in the event the subsequent 
visit is delayed or the study product is damaged or lost. Each bott le will be appropriately 
labeled in accordance with the regulatory specifications and requirements. Each product 
(Gelesis100  or placebo) will have a unique serial number as part of the label. The labels 
will have  6 languages: English, French, Danish , Czech , Italian,  and Spanish , in 
accordance with language requirements in US, Canada,  and the European Economic Area 
(EEA) [status: 1/2007] . 
 
9.1.4 Responsibilities  
The Investigator (or designee) will maintain an accurate record of receipt of the 
investigational  product as shipped by the Sponsor , including the date received , the batch 
number, and the serial number . One signed copy of this receipt will be returned to the 
Sponsor  when the contents of the shipment have been verified.  
 
The personnel in charge of the storage and dispensation of the investigational product 
will insure that the product is securely maintained as specified by the Sponsor and in 
accordance with the regulatory requirements.  
 
The investigational product will be used for the purpose of this st udy only, and will be 
dispensed in accordance with the Investigator’s prescription. It is the responsibility of the 
Investigator to ensure that an accurate record of investigational product dispensed and 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
36/86 returned is maintained.  The product disposition reco rd will specify the amount dispensed 
to each subject and the date of dispensation. The inventory record will be available for 
inspection at any time. At the completion of the study, the Investigator (or designee) will 
make available copies of this inventor y record to the Sponsor (or designee) upon request.  
 
Any quality issue noticed with the receipt or use of the investigational product by the 
Investigator (or designee) should be promptly notified to the Sponsor (or designee).  
 
9.1.5 Storage Conditions  
The investigational product will be sent by the Sponsor  to the Investigator according t o 
local regulatory requirements . It will be stored at the site, in a secure and safe place, 
between 5 C (41F) and 30C (86F), under the responsibility of the Investiga tor or other 
authorized individual.  
 
9.1.6 Administration Method  
At each dosing of study product, a subject will consume 3 capsules . Damaged capsules 
should not be used. Capsules will be self -administered orally by the subjects 20 to 30 min 
before meals  at lunch and dinner, with approximately  100 mL  of water . After the 
capsules are taken , subjects will wait 5 to 10 min and then proceed to slowly drink  
500 mL of water over a period of up to 10 min. After this water  intake , subjects will wait 
an additiona l 10 min  before beginning to consume their meal in a slow manner.  Drinking 
additional water during and after the meal is highly recommended.  
 
9.1.7 Treatment of Overdose  
Overdose  with Gelesis100  may cause nausea, vomiting, flatulence, bloating, abdominal 
pain, constipation, diarrhea, or other unexpected side effects. The Investigator is 
responsible for any decision regarding  the treatment of the overdose.  
 
9.1.8 Compliance Assessment  
Compliance will be assessed by counting of capsules remaining in each bottle, at each 
visit.  
 
Product  accountability will be under Investigator’s direct supervision. The appropriate 
electronic case report form (CRF) will be completed regarding the dosing and the 
treatment assignment.  
 
9.1.9 Retrieval and/or Destruction  
At the completion of the study, investigational product, including all empty, partially 
used, and unused bottles, will be returned to the Sponsor (or designee). Detailed 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
37/86 treatment and accountability logs will be established and countersigned by the 
Investi gator and the Monitoring Team Representative (or designee).  
 
The Investigator will not destroy the unused investigational product unless requested 
officially in writing by the Sponsor.  
 
9.2 Concomitant Medication  
9.2.1 Prohibited Medication  
 Oral contraceptives  
 Anti-obesity medications or other medications (including herbal preparations  
especially those containing amphetamine -like compounds ) for weight reduction  
 Antidiabetic medications  (except stable dose of metformin , ≤ 1500 mg/day, in 
subjects w ith type 2 diabetes already on treatment)  
 Systemic corticosteroids  (oral, rectal, injectable)  
 Thyroid hormones or preparations (except stable dose of replacement therapy in 
subjects already on thyroid hormones or preparations)  
 Diuretics  
 Estrogen (except st able dose of replacement therapy or non -oral contraceptive  in 
subjects already on treatment ) 
 Any other medication or product known to cause weight loss or weight gain  
 Change in m edications treating dyslipidemia  (including change in dose)  
 Change in m edications treating hypertension  (including change in dose)  
 Any medication affecting gastrointestinal motility  
 Addictive medications including a mphetamines, barbiturates, cannabinoids, 
cocaine, opiates, and phencyclidine  
 
The intake of prohibited medicatio n for more than 7 days in case of  oral formulation and 
at least once in case of  injectable formulation is a major protocol deviation  and will result 
in subject discontinuation from the study.  The oral intake of prohibited medication for 7 
days or less is a  minor protocol deviation and will not result in subject discontinuation 
from the study.  
 
9.2.2 Permitted Medication  
 Non-oral medications used for contraception  
 All other drugs than those listed in Section 9.2.1, if considered necessary for the 
subject, wi th a stable dose (when possible), at the  discretion of the Investigator  (if 
they are not taken within 2 h before and after the study product administration  in 
case of oral drugs ) 
 
Subjects should avoid the in take of any oral drugs and/or vitamin supplements within 2 h 
before and after the study product  administration  to prevent a potential reduction in the 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
38/86 efficacy of these drugs /vitamin supplements  (secondary to a decrease in their i ntestinal 
absorption ). 
 
At selected sites where v itamins are measured, subjects taking vitamin supplements  
should continue the ir intake without any change of the dose or the timing of 
administration during the study.  
 
9.3. Diet and Life -Style Recommendations  
9.3.1 Diet  
During the entire study (from the Baseline Visit to the last Follow -up Visit), a 
hypocaloric diet will be prescribed to all subjects. The energy requirement will be 
calculated by the dietitian based on the estimated basal metabolism rate and the physical 
activity of each subject at the Screening Visit  using the Harris -Benedict equation (1 4). 
From this amount of energy, 300 kcal/day will be subtracted to obtain the recommended 
hypocaloric diet. The energy content  will not be less than 1,200 kcal/day.  
 
The da ily dietary intake will include approximately 45% to 5 0% of calories from 
carbohydrate, up to 30% of calories from fat (< 10% saturated fat, < 200 mg cholesterol), 
and 20% to 2 5% of calories from protein. Meals should be consumed  slowly  with water 
as instructed . The meal time should remain relatively unchanged during the study. The 
interval between lunch and dinner should be at least 5 h. The average daily alcohol 
consumption should be ≤ 20 g/day (or ≤ 140 g/week). The daily sodium intak e of each 
subject should remain unchanged.  
 
The compliance of the subjects with the proposed diet will be assessed by a dietitian at 
each dietary interview during the study.  The instructions on water intake should be 
reinforced if there is an increase in s erum albumin from baseline of more than 1 g/L at 
Visit 4 (Day 15), Visit 5 (Day 29), and Visit 9 (Day 85).  
 
9.3.2 Life -Style  
Subjects will be instructed to have moderate -intensity physical activity ( e.g., 30 min 
walking every day) during the study.  
 
Subjec ts will be instructed to continue, without change, their smoking habits during the 
study.  
 
The compliance of the subjects with the proposed life-style  will be assessed by the 
Investigator ’s Team  at each visit during the study.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
39/86 10. STUDY DURATION  
10.1 Stud y Duration per Subject  
10.1.1 Screening Period  
The maximum duration of the screening period is 21 days.  
 
10.1.2 Baseline Period  
The duration of the baseline period is 1 day.  
10.1.3 Treatment Period  
The duration of the double -blind treatment period  (active product  versus placebo)  is  
168 days with a visit window of  2 or 3 days (see Section 12.1) . 
 
10.1.4 Post-Treatment Follow -up Period  
The duration of the follow -up period is 28 days with a visit window of 3 days for Visit 14  
but no visit window for Visit 13 (see Section 12.1) . 
 
10.2. Total Study Duration  
The total study duration will be approximately 2 years (including approximately 1 and 
half years  for enrollment).  The start date is expected to be during the second half of 2014 
and the end date during the first half of 2017 . 
 
11. STUDY ENDPOINTS  
When hydrated , Gelesis100  has some weight by itself . At any time following the first day 
of Gelesis100  administration, s ubjects may accumulate up to 1  kg of hydrated Gelesis100  
in their gastrointestinal tract. There fore, it is likely to observe  an initial weight gain 
during the first days or weeks of treatment until the extra weight is counter -balanced by 
the weight loss caused by Gelesis100 . An interval of 2 days is required for any remaining 
Gelesis100  to be elimin ated from  the gastrointestinal tract. For these reasons, t o ensure 
that the weight of Gelesis100  does not mask the true amount of weight loss, the end of 
treatment assessment of body weight and weight -related parameters will be performed on 
Day 171, approx imately 60 h after the last administration of Gelesis100 . 
 
11.1 Effectiveness  Endpoints  
11.1.1 Co-Primary Endpoint s 
 Body weight (percent change from baseline to Day 171) 
 Body weight responders ( ≥ 5% weight loss from baseline to Day 171) 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
40/86 11.1.2 Secondary Endpoints  
 Plasma glucose status (normal, impaired, diabetic) (change from baseline to  
Day 171) 
 Plasma glucose ( percent change from baseline to Day 171) 
 HOMA -IR (percent change from baseline to Day 171) 
 HbA1c  (change from baseline to Day 171) 
 BMI (change from baseline to Day 171) 
 
11.1.3  Tertiary  Endpoints  
 Body weight responders ( ≥ 10% weight loss from baseline to Day 171) 
 Estimated excess body weight (percent change from baseline to Day 171) 
 Body weight status (normal, overweight, obese) (change f rom baseline to  
Day 171) 
 Waist circumference (change from baseline to Day 171) 
 Serum insulin ( percent change from baseline to Day 171) 
 Serum C-reactive protein (CRP)  (change from baseline to Day 171) 
 Serum total cholesterol (percent change from baseline t o Day 171) 
 Serum LDL  cholesterol (percent change from baseline to Day 171) 
 Serum high -density lipoprotein (HDL) cholesterol (percent change from baseline 
to Day 171) 
 Serum total cholesterol/HDL cholesterol ratio (change from baseline to Day 171) 
 Serum trig lycerides (percent change from baseline to Day 171) 
 Supine and standing SBP and DBP (change from baseline to Day 171) 
 Food intake (change from baseline to Day 169) 
 Food habits (change from baseline to Day 169) 
 Satisfaction  (overall impression on Day 169) 
 Impact of weight on quality of life (IWQOL)  (change from baseline to Day 171)  
(at selected sites ) 
 
The secondary and tertiary effectiveness endpoints are for supportive purposes only.  
 
11.2 Safety Endpoints  
11.2.1 Adverse Events  
 All AEs and SAEs  (including ADEs and SADEs)  
 
11.2.2 Physical Examination  
 Full physical examination (excluding pelvic and rectal examination)  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
41/86 11.2.3 Vital Signs  
 Supine and standing SBP and DBP  
 Supine and standing heart rate  
 
11.2.4 Laboratory Tests  
 Hematology including hemoglobin, hematocrit, red blood cell count, reticulocyte 
count, white blood cell count with differential, and platelet count  
 Blood chemistry including plasma glucose and serum sodium, potassium, 
chloride, calcium, phosphorous, magnesium, blood urea nitro gen, creatinine, uric 
acid, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, total 
protein, albumin, total bilirubin, alkaline phosphatase, lactate dehydrogenase, 
alanine aminotransferase, aspartate aminotransferase, and gamma 
glutamyltr ansferase  
 Vitamins including vitamin A, vitamins B 1, B 2, B 6, B 9, and B 12, vitamin D, and 
vitamin E  (vitamins will be measured  in approximately 60 subjects from the sites 
of Czech Republic and the site of  Rome,  Italy)  
 
11.3 Assessment Methods  
All the assessments, unless otherwise specified, will be performed in the morning 
(between approximately 7 am and 10 am), before product intake, on fasting subjects (10 
to 12 -h fast)  with no moderate  or intense physical activity within the past 12 h . Physical 
examination , dietary interview, and electrocardiogram (ECG)  can be performed  at any 
time during the day regardless of food or investigational product intake.  
 
11.3.1 Clinical  
11.3.1.1 Physical Examination  
A full physical examination (excluding pelvic and r ectal examination) will be performed 
by the Investigator.  The physical examination  will cover the following areas : 
- general appearance  
- eyes 
- ears, nose, throat  
- neck  
- respiratory  
- cardiovascular  
- endocrine  
- hepatic  
- gastrointestinal  
- genitourina ry 
- peripheral vascular  
- neurological  
- musculoskeletal  
- extremities  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
42/86 - lymphatic  
- dermatological  
- allergies  
- psychiatric  
 
11.3.1.2 Body Weight  
Body weight should be obtained with the subject wearing undergarments or very light 
clothing and no shoes, and with an empty bladder. The same scale should be used 
throughout the study. The use of a balance -beam scale is recommended. If a digital scale 
is used, testing with standard weights is of particular importance. The scale needs to be 
calibrated within 12 months prior to the first Screening Visit  and its precision should be 
verified every 4 months after the first Screening Visit . The floor surface on which the 
scale rests must be hard and should not be carpeted or covered wi th another soft material 
and the scale must not be moved during the entire duration of the study. The scale should 
be balanced with both weights at zero and the balance bar aligned.  The subject should 
stand in the center of the platform as standing off -center may affect the measurement. 
The weights are moved until the beam balances (the arrows are aligned). The weight is 
read and recorded. Self -reported weights are not acceptable. Su bjects must not read the 
scale themselves.  
 
11.3.1.3 Waist Circumference  
Waist circumference should be measured according to the established methods. It is taken 
at the midpoint between the lower rib margin and the iliac crest. The circumference 
should pre ferably be measured on subjects while they are semi -clothed (i.e., waist 
uncovered with the subjects wearing underclothes only). If it is not possible to follow this 
procedure, the alternative is to measure the circumference on subjects without heavy 
outer  garments with all tight clothing, including the belt, loosened and with pockets 
emptied. Subjects should stand with their feet close together (no more than 15 cm apart) 
with their weight equally distributed on each leg. Subjects should be asked to breathe  
normally and at the time of the reading of the measurements asked to breath e out gently. 
This will prevent subjects from contracting their muscles or from holding their breath. A 
plastic metric tape should be used. The length of the tape should be checked  before 
starting the study and the length should be re -checked against a standard measure at least 
once a month and the tape should be replaced as appropriate. The two sides of the tape 
should be differently colored or have a scale only on 1 side. If the t ape is uniformly 
colored, with reading on both sides, 1 side should be blanked out. The tape should be 
held firmly and its horizontal position should be ensured. The tape should be loose 
enough to allow the recorder to place 1 finger between the tape and t he subject’s body. 
The importance of the tightness of the tape should be emphasized. It is recommended that 
the observer sits beside the subject while the readings are taken. Three measurements will 
be performed and recorded.  
 
11.3.1.4 Blood Pressure  
SBP a nd DBP will be measured using a calibrated device. The device will be  a mercury 
sphygmomanometer with a cuff appropriate to the subject’s arm girth (obesity cuff). If 
not available, another device may be used which is calibrated carefully in proportion to a 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
43/86 mercury sphygmomanometer. Aneroid manometer is not recommended. The calibration 
of the device will be according to the site -specific guidelines  and requirements . The same 
model of device will be used for each subject throughout the study.  Blood pressure 
should be measured under standardized conditions, on the same arm. Bo th SBP and DBP 
should be recorded. The disappearance of sound (Korotkov phase V) should be used for 
the diastolic reading. Blood pressure should be measured in both supine position (after 
the subject has r ested comfortably for at least 5 min) and standing position (after 2 min). 
At the Screening Visit, supine blood pressure should be checked in both arms on two 
consecutive readings separated by 2 min. The arm with the higher SBP will be 
determined at this visit  based on the mean of two consecutive readings , and blood 
pressure should be measured in this arm throughout the study. At each other visit, two 
readings of supine blood pressure separated by 2 min should be recorded.  
 
11.3.1.5 Heart Rate  
Heart rate (pulse) will be measured over 1 min  at the time of th e second measurement of 
supine blood pressure and at the time of the measurement of standing blood pressure and 
the results will be recorded.  
 
11.3.1.6 Electrocardiogram  
ECG  will be obtained using a 12 -lead cardiograph. The maintenance of the device will b e 
according to the site -specific guidelines and requirements. ECG will be performed after a 
15-min rest in supine position.  
 
11.3.1.7 Binge Eating Disorder  
The questionnaire on eating and weight patterns -revised (QEWP -R) abbreviated version 
will be used to  identify subjects with binge eating (Appendix 1).  Subjects are excluded 
from enrollment if the answer to question 1 1 is yes  except if they are considered as mild 
binge eaters  according to the Investigator ’s assessment . 
 
11.3.1.8 Food Intake  
Food intake  will be assessed by food diary. The diary will include all the meals consumed 
during any 2 consecutive weekdays and 1 weekend day before the visit. The assessment 
will include global food intake (including fluid intake), carbohydrate intake, fat intake, 
protein intake, and fiber intake.  
 
11.3.1.9 Food Habits  
Food habits  will be assessed by a questionnaire (Appendices 2 and 3).  
 
11.3.1.10 Satisfaction  
A questionnaire  will record  the thoughts of the subjects regarding the investigational 
product  (Appendix 3) . The questionnaire will be completed by the  subjects at the last 
treatment  visit. 
 
11.3.1.11 Impact of Weight on Quality of Life 
The IWQOL  questionnaire will ask subjects at selected sites about the impact of weight 
on their quality of life  (Appendix 4) . 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
44/86 11.3.1.12 Adverse Events  
All AEs  and SAEs will be recorded (see Section 13).  
 
11.3.2 Biological  
11.3.2.1 Blood Parameters  and G enomic  Tests  
Blood samples will be collected by venipuncture and shipped to the local or central 
laboratory as per laboratory instructions (provided in a laboratory manual).  
 
Insulin resistance will be measured by HOMA -IR (15), which is calculated by 
multiplying fasting serum insulin (μU/mL) by fasting plasma glucose (mmol/L) and 
dividing by 22.5.  
 
Serum amylase results will be r eported as total serum amylase and pancreatic serum 
amylase.  
 
Genomic tests will include the analysis of copy number variation of AMY1 gene (gene 
encoding salivary amylase) and additional analysis  of several genes involved in obesity 
and type 2 diabetes ( BDNF, CAPN10, FTO, KCNJ11, LEPR, MC4R, NEGR1, NPC1, 
PCSK1 , PPARG , SH2B1 , SLC16A13, and TCF7L2  genes ). Blood samples for the 
extraction and analysis of d eoxyribonucleic acid will be shipped to the central laboratory 
as per laboratory instructions. The results of genomic  tests together with the result s of 
serum amylase will be correlated to  weight -related and metabolic parameters at baseline 
and their evolu tion during  the study, in different populations.  
 
The total blood requirement per subject for all blood samplings will be approximately  
70 mL over approximately 31 weeks.  An additional 25 mL of blood per subject will be 
drawn during the entire study at sites where vitamins should be measured  and 5 mL of 
blood per subject will be drawn at a single visit for genomic  tests. 
 
11.3.2.2 Urine Parameters  
Urine samples will be col lected from a morning spot. The tests will be performed at the 
Investigator’s site (pregnancy test, drug screen). The subjects should empty their bladder 
(and discharge the urine) around 6 am, drink approximately  1 glass  of water, and wait 
approximately 2 h before the urine samplings.  
 
Urine drug screen will detect amphetamines, barbiturates, cannabinoids, cocaine 
metabolites, opiates, and phencyclidine.  
 
12. VISITS  
12.1 Schedule  
This is an outpatient study (see Section 2 Study Flow Chart ). The assessments of Visit 1 
(Screening Visit) can be done over several days within the screening period. Visit 1 3 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
45/86 should occur  2 days after Visit 12. The other visits can take place within ± 2 days (up to 
Visit 9) and ± 3 days (after Visit 9) of the sche dule.  
 
Visit 13 should be avoided during the extended holiday period of December/January (the 
last week of December and the first 2 weeks of January). To reach this objective, Visit 2 
should not be scheduled during the last 3 weeks of July.  
12.2 Assessment s 
The following procedures will be performed (see Section 11 Study Endpoints ): 
 
12.2.1 Visit 1 (Screening Visit; Day -21 to -1) 
 Informed consent (women of childbearing potential are requested to use a 
medically approved contraceptive method during the enti re study)  
 Demographic characteristics (gender, age, ethnic origin)  
 Menopausal status (and estrogen replacement therapy status)  
 Smoking status  
 Medical history  
 Physical examination  
 Height  
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 ECG  
 Binge eating disorder (QEWP -R) 
 Dietary interview (calculation of the energy requirement)  
 Serum pregnancy test (women of childbearing potential only)  
 TSH  
 Urine drug screen (test performed at the Investigator’s site)  
 HbA1c  
 Hemato logy 
 Blood chemistry  
 Previous (within 1 month) and concomitant medication record s 
 AEs and SAEs records  
 
12.2.2 Visit 2 (Baseline Visit; Day 0)  
 Physical examination  
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary prescription)  
 Food intake  
 Food habits  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
46/86  IWQOL  
 Serum amylase (blood can be col lected at any of the Visits 2, 3, 4, 5, 9, or 13)  
 Genomic tests  (blood can be collected at any of the Visits 2, 3, 4, 5, 9, or 13 ) 
(tests not mandatory)  
 Serum pregnancy test (women of childbearing potential only)  
 Urine pregnancy test (women of childbearing potential only) (test performed at 
the Investigator’s site)  
 Serum i nsulin  
 HbA1c  
 Serum CRP  
 Hematology  
 Blood chemistry  
 Vitamins  
 Concomitant medication reco rd 
 Randomization  
 Dispensation of study product  (administration begins the following day)  
 AEs and  SAEs records  
 
12.2.3 Visit 3 (First Double -Blind Visit; Day 8 ± 2) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Plasma glucose  
 Serum insulin  
 Concomitant medication record  
 Investigational p roduct accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2.4 Visit 4 (Second Double -Blind Visit; Day 1 5 ± 2) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Plasma glucose  
 Serum insulin  
 Serum albumin  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
47/86  AEs and SAEs records  
 
12.2.5 Visit 5 (Third Double -Blind Visit; Day 2 9 ± 2) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Food intake  
 Plasma glucose  
 Serum insulin  
 Serum albumin  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2.6 Visit 6 (Fourth Double -Blind Visit; Day 43 ± 2) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and h eart rate)  
 Dietary interview (dietary check)  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2.7 Visit 7 (Fifth Double -Blind Visit; Day 57 ± 2) 
 Weight  
 Waist circumference  
 Vital sig ns (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Food intake  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2. 8 Visit 8 (Sixth  Double -Blind Visit; Day 71 ± 2) 
 Weight  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
48/86  Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2. 9 Visit 9 (Seventh  Double -Blind Visit; Day 85 ± 2) 
 Physical examination  
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Food intake  
 Serum pregnancy test (women of childbearing potential only)  
 Serum insulin  
 TSH  (subjects on replacement therapy with thyroid hormones or preparations 
only)  
 HbA1c  
 Serum CRP  
 Hematology  
 Blood chemistry  
 Vitamins  
 Concomitant medication record  
 Investigational product accountabil ity 
 Dispensation of study product  
 AEs and SAEs records  
 Reinforcement of study -related instructions  
 
12.2. 10 Visit 10 (Eight h Double -Blind Visit; Day 113 ± 3) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary  interview (dietary check)  
 Food intake  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
49/86 12.2. 11 Visit 11 (Ninth  Double -Blind Visit; Day 141 ± 3) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Food intake  
 Concomitant medication record  
 Investigational product accountability  
 Dispensation of study product  
 AEs and SAEs records  
 
12.2. 12 Visit 12 (Tenth  Double -Blind Visit; Day 169 ± 3) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Food intake  
 Food habits and satisfaction  
 Concomitant medication record  
 Investigational product accountability  
 AEs and SAEs records  
 
12.2. 13 Visit 13 (First Follow -up Visit; Day 171; 2 days after Visit 12) (Last visit if 
entering  extension study)  
 New i nformed consent  (subjects entering extension study)  
 Physical examination  
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 IWQOL  
 Serum pregnancy test (women of childbearing potential only)  
 Serum insulin  
 HbA1c  
 Serum CRP  
 Hematology  
 Blood chemistry  
 Vitamins  
 Concomitant medication record  
 AEs and SAEs records  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
50/86 12.2. 14 Visit 14 (Second Follow -up Visit; Day 197 ± 3) 
 Weight  
 Waist circumference  
 Vital signs (supine and standing blood pressure and heart rate)  
 Dietary interview (dietary check)  
 Concomitant medication record  
 AEs and SAEs records  
 
12.3 Definition of Source Data  
The list of information considered as source data that must be shown in the subject’s 
chart  is provided in Appendix 5. 
 
13. SAFETY MONITORING AND REPORTING  
13.1 Adverse Event  and Device  Deficiency  
13.1.1 Investigational Product in  this Clinical Study  
In this clinical study, the investigational product, Gelesis100, is considered  as a medical 
device. Therefore, all safety monitoring and reporting procedures are governed by 
medical device guidelines and regulations.  
 
13.1. 2 Definition s 
An AE is any untoward medical occurrence (sign, symptom, illness, abnormal laboratory 
value, or other medical event) i n a subject, whether or not related to the investigational 
medical device. This includes events related to the procedures involved (any procedure in 
the Clinical Investigation P lan). 
 
A SAE is any AE that:  
- led to death  
- resulted -in a life -threatening condition  
- resulted -in a permanent impairment of a body str ucture or a body function  
- required inpatient hospitalization or prolongation  of existing hospitalization  for ≥ 24 h  
(elective hospitalizations and/or hospitalizations for treatment of pre -existing conditions 
that did not worsen from baseline are not considered AEs and should not be reported as 
SAEs)  
- resulted -in a medical or surg ical intervention to prevent permanent impairment to a 
body structure or a body function  
- led to fetal distress, fetal death or a congenital abnormality, or birth defect  
 
A device deficiency  is an inadequacy of the medical device with respect to its identity, 
quality, durability, and safety (e.g., use errors and inadequate labeling). Medical device 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
51/86 deficiency can lead to an adverse device effect (ADE) or a serious ADE (SADE) (see 
below).  
 
For the purpose of this study and for reporting purposes, all device deficiencies that could 
have led to SAEs, if suitable action had not been taken or intervention had not been 
made , or if circumstances had been less fortunate , will also be considered as SAE.  
An ADE  is an AE with a reasonable causal relationship to the use of the investigational 
medical device (i.e.,  an AE assessed as either “most probably related” or “possibly 
related” to the use of medical device ) (see Section 13.1.3).  
 
An unanticipated ADE  (UADE)  is an ADE not previously reported or an A DE that 
occurs with specificity, severity, frequency , or outcome  that is not consistent with the 
current Investigator’s Brochure  (8). 
 
A SADE is a SAE with a reasonable causal relationship to the use of the investigational 
medical device (i.e., a SAE assessed as either “most probably related” or “possibly 
related” to the use of medical device).  For Canada, this definition is equivalent to the 
Canadian definition of an incident.  
 
An unanticipated SADE  (USADE) is a SADE not prev iously reported  or an SADE that 
occurs with specificity, severity, frequency , or outcome  that is not consistent with the 
current Investigator’s Brochure.  In US, this definition is equivalent to the definition of an 
UADE  in Medical Device Reporting regulation at Title 21.  
 
13.1. 3 Adverse Event and Device Deficienc y Recording, Assessment, and Reporting 
Procedure  
All AE s regardless of seriousness or relationship to the investigational medical device 
including those occurrin g during the screening period (after the signature of the Informed 
Consent Form) are to be recorded in the appropriate electronic CRF.  
 
AEs reported by subject will be  discuss ed in  details  and recorded by the Investigator at 
each visit. AEs will be collect ed until 28 days after the last administration of the 
investigational medical device  (i.e., until subject terminates his/her participation in the 
study).  
 
The Investigator should specify the date of onset, severity, action taken with respect to 
the investi gational medical device , corrective treatment, outcome, and whether or not 
there is a reasonable possibility that the AE may have been caused by the use of the 
investigational medical device . 
 
AEs are graded as follows:  
 Mild: sign or symptom, usually transient, requiring no special treatment and 
generally not in terfering with usual activities.  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
52/86  Moderate: sign or symptom, which may be ameliorated by simple therapeutic 
measures, ma y interfere with usual activity.  
 Severe: sign or symptom intense or debilitating and interfering  with usual 
activities  without being immediately life-threatening. Recovery is usuall y aided 
by therapeutic measures.  
 Very severe: sign or symptom life-threatening . Urgent intervention indicate d. 
 
The assessment of the relationship of an AE to the use of the medical device  is a clinical 
decision based on all available information at the time of the completion of the electronic 
CRF:  
 Most probably related : follows a reasonable temporal sequence fr om medical 
device use , and cannot be reasonably explained by known characteristics of the 
subject ’s clinical data.  
 Possibly related: follows a reasonable temporal sequence from medical device 
use, but could have been produced by the subject ’s clinical stat e regardless of the 
medical device . 
 Probably not related: temporal association is such that the medical device use is 
not likely to have had any reasonable association with the observed event.  
 Not related: no relationship to the use of the medical device  is perceived.  
 
Abnormalities of vital signs and laboratory results are to be recorded as AEs only if they 
are considered by the Investigator as clinically significant (symptomatic, requiring 
corrective treatment, leading to discontinuation, or fulfilling a seriousness criteria).  
 
Any pre -existing conditions or signs and/or symptoms present in a subject prior to the 
Screening Visit should be recorded as medical/surgical history.  
 
In this study, the following events will be reported to the authorities on exped ited basis:  
 All SAEs (including SADEs) will be expeditiously  reported to the relevant 
European Regulatory  Authorities and the Ethics Committees . 
 All newly discovered pregnancies will be expeditiously reported, if required by 
the local regulations . 
 All suspected USADEs will be expeditiously  reported to the US Food and Drug 
Administration (FDA) and the US Institutional Review Board s. 
 All incidents occurring in Canada will be expeditiously reported to Health 
Canada . 
 
All device deficiencies are to be r ecorded in the appropriate electronic CRF.  
 
13.1. 4 Anticipated Adverse Device Effects  
The ADE s anticipated  with the administration of Gelesis100  in overweight or obese 
subjects include nausea, dyspepsia ( heartburn ), abdominal distension ( bloating ), 
flatule nce, abdomina l pain, diarrhea, defecation  urgency, and constipation . These AE s 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
53/86 were observed in the FLOW study.  A comprehensive  list of anticipated ADE s is provided 
in the Investigator ’s Brochure  (8). 
 
13.1. 5 Risk Analysis  
The Sponsor  has established and maintains a process for identifying hazards associated 
with the use of its products, estimating, evaluating, controlling these risks and monitoring 
the effectiveness of the control.  Detailed  information regarding risk analysis  is avail able 
in the Investigator’s Brochure ( 8). 
 
13.1. 6 Precautions to Minimize Risk  
To minimize technical and medical complications, the investigational medical device  
should be used only as instructed in the Clinical Investigation P lan. This includes:  
- adminis tering the prescribed amount of medical device  before lunch and dinner ( 3 
capsules)  
- drinking the prescribed volume of water ( approximately 100 mL + 500 mL ) at the 
prescribed timing before meal  
- consuming food at the prescribed timing (20 to 30 min  after medical device  
administration ) 
 
13.2 Pregnancy  
In case of pregnancy, the investigational medical device use must be discontinued and the 
Sponsor informed. Every effort should be made to follow up the pregnancy until its 
outcome is available.  
 
The Contract Research Organization  (CRO ) Clinical Safety will provide the Investigator 
with the Pregnancy Reporting  Form for completion. If the pregnancy is to be terminated, 
the anticipated date of termination should be provided.  
 
13.3 Responsibilities for Ad verse Event and Pregnancy Reporting  
13.3.1 Responsibilities of the Investigator  
- to inform the Sponsor about all AE s 
- to inform the Sponsor  about all SAE s, newly discovered pregnancies or pregnancy 
outcomes, within 24 h of awareness of the events , by: 
 entering the information about the event into the electronic CRF  
 in case the Investigator does not receive an automatic notification from the 
electronic CRF system of successful SAE submission or electronic CRF data 
entering is not possible:  
- printing the completed section of the electronic CRF (or in case completion of 
electronic CRF is not possible, completion of paper SAE form)  
- signing the completed SAE form  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
54/86 - sending the scanned SAE form by e -mail to the CRO Clinical Safety at 
pharmacovig ilance@easthorn.eu (or in case sending a scan is not possible, faxing 
it to the CRO Clinical Safety at +420  244 462 271) 
- to inform the Sponsor about all device deficiencies  
- to make every effort to follow up the subject to a satisfactory resolution of the safety 
event or until the end of the study  
- to respond to follow -up re quests from the Sponsor/ CRO Clinical Safety  
 
13.3.2 Responsibilities of the Sponsor  
- to ensure that : 
 all AEs are recorded  and reviewed with the Investigators  
 all SAE s are reported t o the relevant European Regulatory  Authorities/Ethics 
Committees as required by the local regulations  
 all newly discovered pregnancies are reported as required by the local regulations  
 all suspected USADEs are reported to the FDA/Institutional Review Board s as 
required by the US regulations  
 all SADE s/incidents are reported to Health Canada  as required by the Canadian 
regulations  
 all device  deficiencies  are recorded and review ed with the Investigators  
- during the course of the study, inform in writing all Investigators about all SAE s 
occurring at any of the participating sites  
- to collect and maintain records of all AE s, device deficiencies, and pregnancies  
 
14. TREATMENT/ STU DY DISCONTINUATION  
14.1 Temporary Treatment  Discontinuation  
The subjects may discontinue the study treatment for a period not exceeding 3 days  for a 
valid medical reason , at the discretion of the Investigator . 
 
14.2 Permanent Treatment /Study  Discontinuation  
14.2.1 Reasons  
The subject may withdraw from the treatment with the investigational product (and the 
study) at any time and irrespective of the reason.  
 
The Investigator will discontinue the investigational product (and the study) for the 
following reasons  (after assessing their clinical relevance) : 
- contraception cessation  
- pregnancy or wish of pregnancy  
- significant intolerance to the study product  
- an increase of ≥ 0.5% point  (≥ 5.5 mmol/mol) in HbA1c from Baseline Visit  in subjects 
with treated or untreated  type 2 diabetes, or any  increase if  the new value falls in the 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
55/86 range of the exclusion criteria for  HbA1c (see Section 8.4)  after confirmation following a  
re-check  at the  next study  visit (or before)  
- an increase of ≥ 10% in total  cholesterol, LDL cholesterol, or triglycerides from 
Baseline Visit  in subjects with elevated lipids at Baseline  Visit,  or any increase if  the new 
values fall in the range of the  exclusion criteria for lipids  (see Section 8.4)  after 
confirmation following a re-check  at the  next study  visit (or before)  
- an increase of ≥ 10 mm Hg in supine SBP and/or supine DBP from Baseline Visit in 
subjects with treated or untreated hypertension , or any increase  if the new values fall in 
the range of the exclusion criteria  for blood pressure  (see Section 8.4)  after confirmation 
following a  re-check  at the  next study  visit (or before),  based on the mean of two 
consecutive readings  
- poor subject compliance with the study procedures and recommendations  and/or major 
protocol d eviation  
- it is the best interest of the subject  (including the need to add prohibited medications ) 
 
The subject is withdrawn from the treatment and the study if the treatment arm is 
unblinded for emergency reasons (see Section 15. 5.4.2) or for a reason other than the 
interim analysis before the end of the treatment . 
 
14.2.2 Procedures  
When confirmed, a permanent treatment/study discontinuation should be recorded by the 
Investigator in the appropriate electronic CRF and, if applicable,  reported t o the rel evant 
Ethics Committee/Institutional Review Board . 
 
Every effort should be made to complete the clinical and laboratory evaluations required 
for Visit s 12 and 1 3 as soon as possible  (combined assessments) . 
 
Subjects who have withdrawn from the treatment/study cannot be re -enrolled in the 
study. Their screening number and randomization number must not be re -used.  
 
15. STATISTICAL CONSIDERATIONS  
This section presents general information about statistical considerations and concepts 
such as randomi zation, stratification, statistical power, and sample size . There will also  
be a brief discussion on analysis methodology, as well as some data conventions. The 
detailed descriptions of statistical analysis methods and data conventions will b e in a 
separat e document, the Statistical Analysis Plan (SAP).  Any post -hoc analyses will be 
identified in the final Clinical Study Report.  
 
15.1 Treatment Arms  
The following treatment arms  will be assessed:  
- active: Gelesis100 2.25 g, twice daily  
- placebo: matching placebo  containing sucrose, twice daily  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
56/86 15.2 Baseline and Visit Windows  
Baseline for a given parameter or endpoint is defined to be the last observation (obtained 
at either the Screening or Baseline Visit) taken before the first study product 
administratio n. The study  visits and visit windows a re Days 8 ± 2, 15 ± 2, 29 ± 2, 43 ± 2, 
57 ± 2, 71 ± 2, 85 ± 2, 113 ± 3, 141  ± 3, 169  ± 3, 171, and 197 ± 3. 
 
15.3 Description of Study Endpoints  
The details of the study endpoints are presented in Section 11.  
 
15.4 Sample Size Determination and Rationale  
For this clinical trial, a  total of 460 subjects  (230 per arm) will be randomized to have 
322 subjects complete the study  (161 per arm) due to an anticipated dropout rate of 30% . 
This sample size will allow establishing both super -superiority and superiority with 
sufficient statistical power  based on the primary endpoint of change in body weight from 
baseline . 
 
The sample size calculation , using PASS  (16), is based on the assumption that there will 
be a clinically meaningful difference  of at least 3.0 % weight loss between  the two arms 
after 24 week s of treatment . This 3.0% is also being used as margin to establish the 
super -superiority ( lower bound of the confidence interva l of Gelesis100 effect ≥  3.0% of  
placebo effect).  With the above sample size, there is 85% statistical power for a 3.0% 
margin super -superiority (i.e., delta of at least 4.5%) with a common SD of 5.0% and a 
type I error rate of 0.05 (one -sided test). The s tatistical formula for the study hypothesis is 
as follows:  
H0: µplacebo - µGelesis100 < 3.0% 
HA: µplacebo - µGelesis10 0 ≥ 3.0%  
Where  µplacebo  is the mean percent change from baseline in the placebo  arm and µGelesis100  is 
the mean percent change from baseline in the Gelesis100 arm.  
 
In addition, with the above sample size, there will be at least  90% statistical power to 
establish that the difference between the two arms is greater than 0 ( i.e., the superiority  
with no margin ), with a common SD of 5.0% and a type I error rate of 0.05 (two -sided  
tests) , with t he null hypothesis that the mean percent change from baseline in primary 
effectiveness endpoint is the same for both treatment arms  and t he alternative hypothesis 
that the Gelesis 100 arm provides a different  mean percent change  in body weight than 
does the placebo arm.  The statistical formula for the study hypothesis is as follows : 
H0: µplacebo - µGelesis100 = 0 
HA: µplacebo - µGelesis100 ≠  0 
Where  µplacebo  is the mean percent change from baseline in the placebo  arm and µGelesis100  is 
the mean percent change from baseline in the Gelesis100 arm.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
57/86 15.5 Randomization, Stratification , Blinding , and Unblinding  
15.5.1 Randomization  
This is a m ulticenter randomized clinical trial with sites from different countries ( US, 
Canada, and several European countries ). Eligible s ubjects will be randomly assi gned to 
the active arm or the placebo  arm based on a randomization schedule. An individual 
independent of the clinical trial team  will develop the randomization schedule.  
 
The randomization will be central and will use mixed blocks of 2 and 4 with a 1:1 ratio of 
active to placebo  to ensure even distribution of active and placebo subjects.  Each arm 
will include  approximately 230 subjects. 
 
The randomization assignment will be made through an interactive web randomization 
system maintained by the CRO . The site representative will log into the eClinical system 
(developed by Clinical Research Technology, Srl.) and enter the information  pertaining 
to the subject to be randomized, and will be notified of the next sequential randomized 
treatment.  
 
15.5.2 Stratification  
The following characteristics at the Screening Visit will be used as stratification factors at 
the time of randomization and the centralized randomization procedure will balance 
treatment arm assignments in each country or combination of countries for the following 
stratification factors:  
- male , BMI < 35,  and normal fasting glucose  
- male , BMI < 35,  and impaired/diabetic  fasting glucose  
- male, BMI ≥ 35, and normal fasting glucose  
- male, BMI ≥ 35, and impaired/diabetic fasting glucose  
- female , BMI < 35,  and normal fasting glucose  
- female , BMI < 35,  and im paired/diabetic  fasting glucose  
- female, BMI ≥ 35, and normal fasting glucose  
- female, BMI ≥ 35, and impaired/diabetic fasting glucose  
 
The selection of these stratification factors is based on the facts that gastric capacity has a 
tendency to be higher in male subjects  and in subjects with higher BMI,  and weight loss 
can be  more important  in subjects with higher fasting glucose ( data from  the FLOW 
study) . 
 
15.5.3 Blinding  
As this is a double -blind trial, the study participants, the Investigators, all other study site 
personnel, the Monitoring Team involved in collecting  the data , the Data Management 
Team  involved in querying the clinical sites , and the Sponsor  will be blinded to treatment 
assigned to the subject  during the entire course of the study . Placebo capsules matching 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
58/86 the size, shape, color, and coating of Gelesis100  will be used fo r blinding the study 
treatment.  
 
The randomization lists containing the assignment of subjects to treatment arms  will be 
securely provided to the person involved in randomizing the subjects (i.e. , the 
WebMaster), who has no role in screening, qualifying,  enrolling, or evaluating study 
subjects. No other study personnel other than the WebMaster and the randomization code 
generator will have access to the ran domization codes for the study.  
 
15.5.4 Unblinding  
To maintain the study blind, treatment unblinding will occur only per the cases specified 
below. The  unblinding will be performed  after all clinical data have been  received, data 
inconsistencies have been resolved, and the database has been  locked, except for the case 
of the interim analysis by an independent statist ician and the emergency unblinding  
including management of a suspected USADE/SADE . 
 
15.5.4.1 Unblinding for Interim Analysis  
An interim analysis is planned to be conducted when approximately 5 0% of the subjects 
have been randomized and completed Visit 13 (Week 24) or early terminated, whichever 
comes first.  The details of this interim analysis are presented  in Section 15.6.  
 
Unblinded treatment assignments for the interim analysis will only be given to the 
independent statistician. For this analysis , there will be no subject level unblinding to any 
other pers onnel in the study  except  the WebMaster and the randomization code generator . 
The summary tables will be unblinded to the treatment arm level and will be presented 
using masked treatment arms . Unblinding of treatment arms  to the Data Monitoring 
Committee  members wil l only occur per their request.  
 
15.5.4.2 Unblinding  for Emergency  
Every attempt will be made to maintain the blind throughout the study.  Breaking the 
blind prematurely will be allowed only under two circumstances:  
- when knowledge of the treatme nt assignment is essential for treating a subject in case of 
an emergency  
- as part of the management of a suspected USADE /SADE  
 
The unblinding of treatment assignment will be performed by:  
 
The Investigator  in case of a suspected SADE if : 
 The information about the treatment assignment is essential for the subsequent 
treatment of the suspected SADE . 
 
Should the need for unblinding the code arise, the Sponsor’s Trial Monitor must be 
contacted immediately via phone and e -mail to approve the unblinding. This p rior 
approval can be waived if there is a life -threatening situation requiring immediate 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
59/86 intervention. However,  the Investigator must notify the Sponsor  (or designee) as soon as 
possible fol lowing the unblinding event.  
 
The CRO Clinical Safety  in case of a suspected USADE /SADE  if: 
 The Regulatory  Authorities /Ethics Committee/Institutional Review Board request 
the information about the treatment assignment . 
 The Sponsor needs the information about the treatment assignment for the 
evaluation of ris k analysis . 
The CRO Clinical Safety performs such unblinding upon approval from the Sponsor. 
After unblinding, the CRO Clinical Safety Manager informs both the Sponsor and the 
Investigator about  the study subject in question.  
 
The unblinding is performed b y logging onto the eClinical system  and enter ing the 
appropria te subject -specific information . The user will follow the prompts for emergency 
unblinding and will be notified of the treatment assignment on the screen. The date and 
reason for revealing the t reatment assignment for the subjects will be captured in the 
eClinical system . Sponsor and CRO Clinical Safety will be notified of the unblinding . 
Sponsor’s Trial Monitor  will follow  up with the site in a case the site did not obtain prior 
approval to unblind.  
 
Subjects who are unblinded for emergency reasons will be d iscontinued from the 
treatment.  
 
15.5.4.3 Unblinding for Final Analysis  
Treatment unblinding and release of the randomization codes of the investigational 
product assignments for the study  will occur if the trial is terminated or , at the time of 
database lock . That is after  all randomized subjects have completed the study  or 
discontinued from the study and all clinical data have been received and data 
inconsistencies have been resolved.  
 
15.6 Interim Analysis  
An interim analysis will be conducted when approximately 5 0% of subjects have been 
randomized and completed Visit 13 (Week 24) or early terminated, whichever comes 
first. 
 
The procedures for this interim analysis  will be based on a standard operating procedure 
that has a well -established firewall to protec t the integrity of the trial. The interim 
analysis  will be performed by an independent statistician, who is not otherwise associated 
with the conduct of this tri al. 
 
The main purpose of this interim a nalysis is to assess:  
- sample size re -assessment to evaluate the sample size estimations, which will serve in 
the planning  of the remainder of the study  
- other  parameters that the Data Monitoring Committee may request  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
60/86 15.6.1 Procedures for Interim Analysis  
 Cutoff dates for collection of electronic CRFs, data querying, database lock , and 
analysis are established based on an estimated target date of the approximat ely 
50% of  subject completing 24 weeks of treatment  or early terminated . 
 All data available  by the cutoff date is entered, validated, queries generated and 
resolve d or pending queries documented.  
 The datab ase is locked.  
 The locked database is saved in a dr ive to which only the independent statistician 
responsible for the interim analysis  has access . 
 
Using the data obtained in this interim analysis , the independent statistician will prepare 
safety summaries and calculate the following metrics for the primary endpoint:  
 Mean percent change at Week 24, the SD and the observed number of subjects in 
the active arm.  
 Mean percent change at Week 24, the SD and the observed number of s ubjects in 
the placebo arm.  
 The dropout rate at the time of the interim analy sis for both arms.  
 The conditional p ower (CP) analysis of the study at the time of the interim 
analysis (1 7) (the method for this  calculation is provided in below).  
 The revised sample size requirement based on this interim analysis (1 8) (the rule 
and metho d for sample size recalculation are provided below ). 
 
15.6.2 Conditional Power Calculation  
The CP will be calculated according to the below formula using the mean percent 
changes in the active  arm compared to placebo  arm: 
 
CP (f1,z1) = Φ { z1/√𝑓1 (1−𝑓1) – zα/√(1−𝑓1)} 
where:  
 CP (f1,z1) is the CP at the interim analysis  
 Φ{.} is the cumulative distribution function of a standard normal distribution  
(μ = 0, σ2 = 1) 
 f1 is the fraction of subjects  enrolled and used in the interim analysis  before 
decision of increasing the sample size  
 zα is the upper α quintile for standard normal distribution  
 z1 is the standardized normal, the z  score will be obtained from the following 
formula:  
 
            z1 = (µa - µc - 3)/√[𝜎𝑎2/ 𝑛𝑎+ 𝜎𝑐2/ 𝑛𝑐 ] 
            where:  
o µa = the mean percent changes at Week 24 for the subjects in the active 
arm 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
61/86 o µc = the mean percent changes at Week 24 for the subjects in the placebo  
arm 
o σa = the SD  of percent changes at Week 24 for the subjects in the active 
arm 
o σc = the SD  of percent changes at Week 24 for the subjects in the placebo  
arm 
o na = the number of subjects in the active  arm used in the interim analysis  
o nc = the number of subjects in the placebo  arm used in the interim analysis  
o a = the active arm  
o c = the place bo arm  
 
The resulting CP will be used to determine whether the sample size should  be increased 
or remain unchanged.  
 
15.6.3 Rule and Method for Increasing Sample Size  
 If the CP < 36% , the sample size will not be increased and the study will continue 
as is. 
 If the CP is ≥ 36% and < 8 5%, the sample size may be adjusted to retain the 
original power of 8 5%. 
 If the CP is ≥ 85%, the study will continue as is . 
 
Regardless of the size of the CP, the study sample size will not be reduced.  
 
15.6.4 Data Provided to Data Monitoring Committee  
The Data Monitoring Committee  will recei ve a statistical report.  The details on the 
content of the report will be  described in the Data Monitoring Committee  charter.  
 
15.6.5 Stopping Rule  
The study will not be stopped for overwhel ming effectiveness  reasons. However, the 
Data Monitoring Committee  may recommend stopping the study for safety reasons at any 
time during the trial. The Investigator may decide to stop the study for reasons described 
in Section 14.2.1. The Sponsor may also  decide to stop the study for safety or other 
reasons at any time during the trial  (see Section 22.1) . 
 
15.6.6 Stopping Rule Provided to Sponsor by Data Monitoring Committee  
The Data Monitoring Committee  will make recommendations to the Sponsor on the 
samp le size adjustment and any safety concerns.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
62/86 15.6.7 Type I Error Rate Adjustment  
There will be no t ype I error rate adjustment as there is no intention to stop the study for 
effectiveness  benefit. In addition, the sample size is planned to be increased when the 
interim CP is promising  and this will protect the type 1 error ra te (18). 
 
15.7 General Statistical Considerations  
All collected study data will be presented in subject data listing s. Statistical analyses will 
be performed using SAS® for Windows, version 9. 3 or later. Descriptive statistics 
(number of observations , mean, SD, median, minimum , and maximum  values ) will be 
calculated by treatment arm for continuous variables. Frequencies  and percentages will 
be presented by treatment arm for categorical variables.  
 
15.7.1 Analysis Populations  
15.7.1.1 Intention -to Treat Population  
The ITT population is defined as all randomized subjects.  
 
15.7.1.2 Per Protocol Population  
The per protocol  (PP) population refers to all randomized subjects who were successfully 
randomized, treated, and stayed on their assigned treatment w ith no major protocol 
deviation . 
 
15.7.1.3 Safety Population  
The safety population is defined as any subject receiving the treatment after 
randomization. This population will be used for the analysis of safety parameters.  
 
15.7.2 Covariates  
For effectiveness  analyses, the stratification factors and the respective baseline values  for 
the endpoint will be used as covariates in the analysis models.  
 
15.7.3 Missing Data  
For effectiveness  evaluation , missing data points will be imputed  using multiple 
imputation approach. This approach is robust and the least bias ed for the missing at 
random cases. This method will be detailed in th e SAP.  
 
15.7.4 Multiple Comparisons and Multiplicity  
For the co -primary endpoints , there will be no type I error adjustment.  
 
For the secondary endpoints , the Closed Test procedure will be used.  All the secondary 
endpoints will be ordered prior to database  lock and tested according to the order . 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
63/86 15.7.5 Subgroup Analysis  
Several subgroup analyses will be conducted for the stratification factors as well as the 
pre-specified secondary endpoints. Subgroup analyses will also be performed  based on 
the results of serum amylase and genomic tests . The detail of these subgroup analyses 
will be presented in the SAP.  
 
15.8 Statistical Methods  
A SAP will be developed and approved before the database is locked. The SAP will 
present the detailed statistical methodology to be used in analyzing the effectiveness  and 
safety data from this trial.  
 
All the effectiveness  endpoints presented here will be conducted using both the ITT and 
the PP  populations. All safety analys es will be conducted using the safety population.  
 
All data collected will be summarized according to the variable type:  
 Continuous data summaries will include:  
o Number of observations, mean, SD, median, minimum , and maximum 
values  
o ANCOVA  with the stratification factors and the respective basel ine values 
for the endpoint in the model for inferential statistics  
 Categorical data summaries will include:  
o Frequency counts and percentages  
o Logit model with the stratification factors and the respective baseline 
values for the endpoint in the model for inferential statistics  
 Time -dependent data:  
o Cox proportional hazards model will be used to analyze time -dependent 
data 
o Kaplan -Meier will be used to depict the time to event data  
 
15.8.1 Subject Disposition  
The disposition of all subjects who sign an Informed C onsent  Form will be provided. The 
numbers of subjects screened, randomized, completed, and discontinued during the study, 
as well as the reasons for all post -randomization discontinuations will be summarized by 
treatment arm. Disposition and reas ons for study discontinuation will also be provided as 
a by-subject listing.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
64/86 15.8.2 Demographics and Baseline Characteristics Analysis  
Demographic and baseline characteristic data will be summarized descrip tively and/or 
presented as a by -subject listing f or the safety population. In addition , all the known 
potential risk factors (e.g., diabetes, dyslipidemia, hypertension) will be tabulated and 
compared between the two treatment arms . 
 
15.8.3 Extent of Exposure to Study Product  
Extent of exposure to the st udy product will be summarized for each arm.  
 
15.8.4 Compliance with Diet, Life -Style,  and Study Product  
Compliance with the diet and life -style recommendations and the intake of the study 
product will be summarized for each arm.  
 
15.8.5 Concomitant Medications/Therapies  
Concomitant medications/ therapies will be summarized separately for the safety 
population. All prior and concomitant medications recorded in the electronic CRF  will be 
coded to all matching Anatomic Therapeutic Classification codes using the most recent 
version of WHO Drug version. Descriptive summaries, by treatment arm, will be 
prepared using the coded term. All concomitant  medications/therapies  recorded in the 
electronic CRF  will be listed.  
 
15.8.6 Effectivenes s Analysis  
15.8.6.1 Primary Analysis  
The primary analysis will be conducted on the ITT population.  
 
Co-primary endpoints  
ANCOVA will be used to compare the percent change in weight from baseline to Day 
171 for the two treatment arms . The stratification factors and baseline weight will be 
included in the analysis and associated treatment difference, 95% confidence interval  
around the difference and P value for the treatment effect will be reported.  
 
The proportion of body weight responders will be presented descriptively by treatment 
arm. Responders in this case will be defined as those subjects who have achieved ≥ 5% 
reduction in body weight compared to baseline. In addition, the Logit model will be used 
to analyze the percent of responders, with the stratification factors and baseline weight in 
the model.  
 
To maintain the trial -wise type I error rate at 0.05, a closed test procedure will be used for 
the secondary and tertiary endpoints. The order of the endpoints will be as follows : 
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
65/86 Secondary and tertiary endpoints  
Analysis of the secondary and tertiary endpoints will be summarized according to the 
variable type:  
- continuous data summaries will be based on  ANCOVA  or Mixed Model using the 
stratific ation factors and the respective baseline values for the endpoint as a covariate  in 
the model  
- categorical data summaries will be based on Logit model using the stratification factors 
and the respective baseline values for the endpoint as a covariate  in the model  
 
15.8.6.2 Supportive Analysis  
To assess the consistency of the primary analysis results, supportive analysis will be 
conducted using the PP population. Statistical methodology for the supportive analyses 
will be the same as that of the primar y analysis, with the exception of the analysis 
population used. The PP population will be used for the supportive analysis while ITT 
population will be used for the primary analysis.  
 
15.8.6.3 Longitudinal Analysis  
Longitudinal data analyses will be conduc ted for selected endpoints ; these will be pre -
specified in the SAP. 
 
15.8.7 Safety Assessments  
15.8.7.1 Adverse Events  
All AEs will be presented by number of episodes and by number of subjects experiencing 
the event in each arm  with information on time of occurrence and duration . 
 
AEs (including ADEs) will be coded using the latest version of MedDRA. Treatment -
emergent AEs  (TEAE s) are defined as events with an onset on or after the first 
randomized treatment. TEAEs will be summarized by treatment arm, System Organ 
Class, and Preferred Term. The following TEAE s summaries will be provided:  
- TEAEs by severity grade  
- TEAEs by relati onship to study treatment  
 
In addition, separate summaries of SAEs  (SADEs)  and AEs (ADEs)  resulting in 
discontinuation of study treatment will be presented.  
 
15.8.7.2 Physical Examination  
All physical examination clinically significant abnormal findings will be listed.  
 
15.8.7.3 Vital Signs  
All data from the vital signs assessments (blood pressure, heart rate) will be listed. The 
data will also be summarized and presented by treatment arm and time point . 
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
66/86 15.8.7.4 Laboratory Tests  
All laboratory values and their changes from baseline will be listed. Laboratory 
measurements will also be summarized as continuous variable and presented by treatment 
arm and time point.  
 
16. STUDY COMMITTEES  
16.1 Steering Committee  
To ensure the proper scientific completion of the study, a Steering Committee (Research 
Coordination Committee) will be established. The Committee will have 7 members. The 
Sponsor and the Principal Investigator will nominate 6 members for this Committee  (2 
members from the Sponsor, 4 members from the investigational sites) . An additional 
member will be nominated from the Monitoring Team of the CRO.  
 
The Steering  Committee should  follow  the overall  progress of the study, ensure smooth 
communication,  seek to solve any unforeseen events affecting the study, and monitor the 
progress of the results.  The Steering Committee will remain blinded throughout the study.  
 
16.2 Data Monitoring  Committee  
To ensure the proper safety of the study, a Data Monitoring Committee will be 
established. The Committee will have 3 members (1 Chairman, 1 Clinical Investigator, 
and 1 Statistician).  
 
The responsibilities  of the Data Monitoring  Committee will be detailed in a charter.  
 
17. ETHICAL CONSIDERATIONS  
17.1 Principles  
The study will be conducted in accordance with the principles established by the 18th 
World Medical Assembly (Helsinki, 1964) and all applicable amendments established by 
the World Medical Assemblie s and the International Conference on Harmonisation (ICH) 
guidelines for Good Clinical Practices (GCP) , and in compliance with European Norm 
(EN) International Organization for  Standardization (ISO) 14155 :2011. 
 
17.2 Informed Consent  
The Investigator (or a  designated representative) should fully inform the subject of all 
relevant aspects of the study. Prior to the study start, the written Informed Consent Form 
must be dated and signed by the subject and by the person who conducted the informed 
consent discu ssion. The Inform ed Consent Form will be translated to the state language 
of the country where the trial will be conducted in accordance with language 
requirements in US, Canada,  and the EEA [status: 1/2007] . The subject will receive the  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
67/86 original or the copy of the translated, dated, and signed Informed Consent Form.  Any 
new significant findings will be communicated to the subject . 
 
17.3 Ethics Committee /Institutional Review Board  
The Investigator must submit this Clinical Investigation Plan  (toget her with the Informed 
Consent Form, the Investigator’s Brochure, the Investigator’s curriculum vitae, and any 
other relevant document) to the appropriate Ethics Committee /Institutional Review Board  
after the approval by the Sponsor , and is required to forw ard to the Sponsor a copy of the 
written and dated favorable opinion signed by the Chairman of the Ethics 
Committee /Institutional Review Board  with information on the composition of the 
Committee /Board . The investigational product will not be released at t he study site and 
the study will not start until this copy has been received by the Sponsor.  
 
Submission in Europe can be done by the Investigator  or the Sponsor (or designee).  
 
Responsibility for coordinating with Ethics Committee/Institutional Review Board  is 
defined in the Investigator/Sponsor (CRO) Contract.  
 
During the course of the study, any amendment to the Clinical Investigation Plan  or any 
update to the Investigator’s Brochure will be sent to the Ethics Committee /Institutional 
Review Board . Any revision to the Clinical Investigation Plan or the  Informed Consent 
Form must be approved by the Ethics Committee/Institutional Review Board prior to  
implementation, unless there is a safety issue for the study subject.  
 
Any additional requirements impose d by the Regulatory Authorities  or the Ethics 
Committee/Institutional Review Board  should be followed.  
 
If requested, a summary of the study outcome will be sent to the Ethics 
Committee /Institutional Review Board  at the end of the trial.  
 
17.4 Confidentiality  
All information provided by the Sponsor or produced during the study is confidential. 
The Investigator and the Sub -Investigators agree to keep this information confidential 
and not to disclose it to any third party without the prior written  approval of the Sponsor. 
The Ethics Committee /Institutional Review Board  members have also the same 
obligation of confidentiality.  
 
18. ADMINISTRATIVE AND REGULATORY PROCEDURES  
18.1 Laws  
The study will be conducted in compliance with laws, regulation s, and guidelines of the 
countries  where the study is conducted ( US, Canada, Europe ). 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
68/86 18.2 Clinical Trials Registration  
This trial will be registered in appropriate clinical trial database(s) consistent with federal 
law and regulation, FDA  guidance, and WHO m andate.  
 
18.3 Curriculum Vitae  
An updated copy of the curriculum vitae of the Investigator and the Sub -Investigators 
will be provided to the Sponsor prior to the start of the study.  
 
18.4 Record Retention  
The Investigator must maintain confidential all stu dy documentation and prevent 
accidental or premature destruction of the documents.  
 
The documents should be retained at least 15 years after the completion of the study. If 
archiving can no longer be ensured by the Investigator, the Sponsor should be infor med 
and a mutually agreed upon alternative should be proposed. The Investigator must notify 
the Sponsor prior to destroying any document before the 15 -year period.  
 
18.5 Data Protection  
The Sponsor should treat the subject’s personal data and the Investiga tor’s personal data 
in compliance with all applicable laws and regulations, and take all appropriate measures 
to protect the data and prevent access to the data by an unauthorized third party.  
 
18.6 Insurance  
The Sponsor certifies that it has a liability i nsurance policy covering the subjects and the 
liability of the Investigator and Sub -Investigators. The insurance policy is in accordance 
with local laws and requirements.  
 
The insurance of the Sponsor does not relieve the Investigator and Sub -Investigators  of 
any obligation to maintain their own liability insurance policy as required by applicable 
law. 
 
18.7 Financial Arrangements  
The sponsor is providing financial support and material through contracts with sites 
participating in the study. Study subjects  may be provided reimbursement for reasonable 
travel expenses and accommodation associated with the completion of study visits , when 
appropriate under local regulation.  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
69/86 19. CLINICAL INVESTIGATION PLAN AMENDMENTS  
Any amendment to the Clinical Investigation  Plan requires a written favorable opinion 
from the Ethics Committee /Institutional Review Board  prior to its implementation, unless 
there are overriding safety reasons. In case a change to the Informed Consent Form 
becomes necessary following the amendment , the Investigator must receive a favorable 
opinion from the Ethics Committee /Institutional Review Board  prior to the 
implementation of the change.  
 
20. CLINICAL INVESTIGATION PLAN  DEVIATIONS  
A Clinical Investigation Plan deviation (protocol deviation) is any change or alteration to 
the procedures stated in the Clinical Investigation Plan, Informed Consent Form, study 
materials (e.g., questionnaires), or recruitment process originally approved by the Ethics 
Committee /Institutional Review Board.  
 
Major protocol deviation is any intentional or unintentional change from the approved 
Clinical Investigation Plan  that adversely affects the risk/benefit ratio of the study,  the 
rights, safety, or welfar e of the study subjects or others,  or the integrity of the study  
(ability to draw conclusions from the study data) , such as any deviation from subject 
inclusion and exclusion criteria or subject informed consent procedures, study medication 
dispensing erro r, etc. 
 
Minor protocol d eviation is any deviation  that does not have the potential to negatively 
impact the willingness of the subjects to participate in the study , the safety of the study 
subject s, or the integrity of study, such as incomplete/inadequate  subject testing 
procedures, non -compl iance with medication regimens, visits performed outside of 
specified visit windows , etc. 
 
The Investigator is not allowed to deviate from the Clinical Investigation Plan  except 
under emergency circumstances to protect rights, safety, and well -being of the study 
subjects.  
 
All protocol deviations are to be reported to the Sponsor . Major protocol deviations are to 
be reported according to  local regulations.  
 
21. STUDY MONIT ORING  
21.1 Responsibilities of the Sponsor  
The Sponsor is responsible to Regulatory  Authorities for ensuring the proper conduct of 
the study (ethical aspects, compliance, integrity and validity of the data recorded). The 
main duty of the Monitoring Team is to help the Sponsor (and the Investigator) to 
achieve this objective. A Monitoring  Plan will be prepared before the start of the study. 
During the study, the Monitoring Team will contact the site at regular intervals (by 
monitoring visits, phone calls, e-mails, letters, or fax) to review the study progress and 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
70/86 discuss any relevant issue . The Monitoring Team must check the electronic CRF entries 
against the source documents.  
 
21.2 Responsibilities of the Investigator  
The Investigator should accept and sign the Clinical Investigation Plan . The Investigator 
is responsible to conduct the stu dy in accordance with the Clinical Investigation Plan , the 
ICH guidelines for GCP, the EN ISO 14155:20 11, and the applicable regulatory 
requirements. The Sub -Investigators appointed to assist the Investigator will be under 
direct responsibility of the Inve stigator. The Investigator agrees to provide reliable data 
as requested by the Clinical Investigation Plan  (through electronic CRF and query ) in an 
accurate and legible manner and to ensure direct access to source documents to the 
Sponsor’s representatives . 
 
22. PREMATURE DISCONTINUATION OF THE STUDY OR 
PREMATURE CLOSE -OUT OF A SITE  
22.1 Decided by the Sponsor  
The Sponsor may decide to discontinue the study or to close the site for the following 
reasons:  
- the number of  subjects who have  completed the study  is considered sufficient  
- the Sponsor has information on the investigational product leading to a doubt about the 
benefit/risk ratio  
- the aim of the study is no longer of interest  
- the Investigator has not included sufficient number of  subject s in the study after a 
reasonable period of time mutually agreed upon  
- the presence of breach by the Investigator of a fundamental obligation  
 
The Sponsor must notify the Investigator in writing and also inform the Regulatory  
Authorities and the Ethics Com mittee /Institutional Review Board . 
 
22.2 Decided by the Investigator  
The Investigator must notify the Sponsor (prior notice of 30 days) of this decision and 
give the reason in writing. The Regulatory  Authorities and the Ethics 
Committee /Institutional Revie w Board  should also be informed.  
 
The Regulatory  Authorities  or the Ethics Committee /Institutional Review Board  may 
suspend or premature ly terminate participation in a clinical investigation at the 
investigation sites for which they are responsible . 
 
The Investigator or authorized designee should  promptly inform the enrolled subjects at 
the site in case of discontinuation/termination of the study . 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
71/86 23. PROPERTY RIGHTS  
All information, documents, and investigational product provided by the Sponsor remai n 
the property of the Sponsor. All the results arising from the study remain the property of 
the Sponsor.  
 
All inventions, formulations, and discoveries that are developed, conceived, and/or made 
by the CRO  and/or the Investigator  based on confidential information received from the 
Sponsor and that are specific to programs, projects, and/or products of the Sponsor will 
be the sole and exclusive property of the Sponsor.  
 
24. COMMUNICATION AND PUBLICATION OF RESULTS  
The Sponsor has t he right to communicate and publish the results of the study at any time  
by proposing authorship to relevant authors from the Investigator’s Team . The 
Investigator has the right to communicate and publish the results of the study by 
proposing authorship to  relevant authors from the Sponsor’s Team and after obtaining 
written approval of the manuscript from the Sponsor. The results of the study will  be 
submitted for presentation at scientific meetings and /or publication in scientific journals. 
The Sponsor has  the right to postpone a presentation/ publication for a period not 
exceeding 1 8 months  after the availability  of the study results . 
 
25. QUALITY ASSURANCE AUDITS AND REGULATORY 
INSPECTIONS  
The Clinical Trial described in this Clinical Investigation Plan  will be subject to Quality 
Assurance evaluations in order to ensure that the trial is performed and the data are 
generated, documented (recorded), and reported in compliance with the ICH E6 G CP 
principles, EN ISO 14155 :2011, and the applicable regulatory requirements. The 
Investigator may be audited by the Sponsor’s Quality Assurance Auditor periodically in 
accordance with Clinical Quality Assurance audit plan. The audit plan will be discussed 
by the Sponsor and the Investigator. The Investigator agrees to  allow the auditors to have 
direct access to the study records for review. The confidentiality of the data audited 
should be respected by all parties. The Investigator should immediately inform the 
Sponsor about the planned audit and the outcome of the aud it by the Regulatory 
Authorities. Corrective actions should be implemented for all problems found during the 
audit.  
 
The I nvestigator agrees to allow direct access to source data/documents, including subject  
journals, during monitoring, auditing and/or ins pection by the Regulatory  Authorities  and 
the Ethics Committee /Institutional Review Board . 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
72/86 26. REFERENCES  
 
1. Bessesen DH. Update on obesity. J Clin Endocrinol Metab, 2008, 93, 2027 -2034 . 
 
2. Prentice AM. The emerging epidemic of obesity in developing countries. Int J 
Epidemiol, 2006, 35, 93 -99. 
 
3. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med, 1993, 119, 655 -660. 
 
4. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes, 1992, 16, 
397-415. 
 
5. Bays HE. Current and invest igational antiobesity agents and obesity therapeutic 
treatment targets. Obes Res, 2004, 12, 1197 -1211 . 
 
6. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab, 2008, 93, 
S89-S96. 
 
7. Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the 
intragastric balloon. Obes Surg, 2004, 14, 991 -998. 
 
8. Gelesis100  Investigator’s Brochure. February  2016 . 
 
9. Heshmati HM , Tacchino R, Ron E, Sannino A, Zohar Y. Attiva , a novel 
superabsorbent biodegradable hydrogel, increases the feeling of satiety in humans. In: 
Program of the 19th Annual Meeting and Clinical Congress of the American Association 
of Clinical Endocrinologists, April 21 -25, 2010; Boston, MA, USA. Abstract  #605 . 
 
10. Astrup  A, Kristensen  M, Gnessi  L, Watanabe  M, Svacina  S, Matoulek  M, Hlubik  P, 
Stritecka  H, Contaldo  F, Pasanisi  F, Heshmati  HM, Zohar Y , Ron  ES, Sannino  A, 
Demitri  C, Saponaro C. Oral administration of Gelesis100, a novel hydrogel, 
significant ly decreases body weight in overweight and obese subjects . In: Program of the 
Joint Meeting of the International Congress of Endocrinology and the Endocrine Society , 
June  21-24, 201 4; Chicago , IL, USA. Abstract # 0897 . 
 
11. Geliebter A, Yahav EK, Gluck ME, Hashim SA. Gastric capacity, test meal intake, 
and appetitive hormones in binge eating disorder. Physiol Behav, 2004, 81, 735 -740. 
 
12. American Diabetes Association . Nutrition recommendations and interventions for 
diabetes. A position statement of the Ame rican Diabetes Association. Diabetes Care, 
2007, 30 (Sup pl 1), S48 -S65. 
 
13. Franz MJ , Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister  LA, 
Hoogwerf B, Mayer -Davis E, Mooradian  AD, P urnell JQ, Wheeler M. Evidence -based 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
73/86 nutrition principle s and recomm endations for the treatment and prevention of diab etes 
and related complications. Diabetes Care, 2002 , 25, 148 -198. 
 
14. Harris JA, Benedict FG. A biometric study of basal metabolism in man. Washington, 
DC: Carnegie Institute of Washington, 1919, Publication 279 . 
 
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta -cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia, 1985, 2 8, 412 -419. 
 
16. PASS 14 Power Analysis and Sample Size Software. NCSS, LLC. Kaysville, Utah, 
USA, ncss.com/software/pass , 2015 . 
 
17. Chen YHJ, DeMets DL, Lan KKG. Increasing the sample size when the unblinded 
interim result is promising. Statist Med, 2004, 23, 1023 -1038 . 
 
18. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are 
promising: a practical guide with examples . Statist Med, 20 11, 30, 3267 -3284 . 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
74/86 27. APPENDICES  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
75/86 27.1 Appendix 1: Binge Eating Disorder  
 
QUESTIONNAIRE ON EATING AND WEIGHT PATTERNS -REVISED  
(QEWP -R) – ABBREVIATED VERSION  
Last Name _____________________  First Name ________________ M.I. ______  
Subject Number _________________  Date _______________________________  
_____________________________________________ ___________________________  
 
Thank you for completing this questionnaire. Please circle the appropriate number or response, or 
write in information where asked. You m ay skip any question you do not wish to answer.  
 
1. Age ________ years  
2. Sex: 1  Male     2  Female  
3. What is your ethnic/racial background?  
1. Black (not Hispanic)  
2. Hispanic  
3. White (not Hispanic)  
4. Asian  
5. Other (please specify)  
________________________  
 
4. How far did you get in school?  
1. Grammar school, junior high school or less  
2. Some high school  
3. High school g raduate or equivalency (GED)  
4. Some college or associate degree  
5. Completed college  
 
5. How tall are you?  
              ________ cm (in) 
6. How much do you weigh now?  
              ________ kg  (lbs) 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
76/86 7. What has been your highest weight ever (when not pregnant)?  
              ________ kg  (lbs) 
8. Have you ever been overweight by at least 4.5 kg (10 lbs) as a child or 6.8 kg (15 lbs) as an 
adult (when not pregnant)?  
              1  Yes     2  No or not sure  
IF YES: How old were you when you were first overweight (at least 4.5 kg (10 lbs) as a child or 
6.8 kg (15 lbs) as an adult)? If you are not sure, what is your best guess?  
              ________ years  
9. How many times (approximately) have you lost 9 kg (20 lbs) or more – when you weren’t 
sick – and then gained it bac k? 
1. Never  
2. Once or twice  
3. Three or four times  
4. Five times or more  
 
10. During the past six months, did you often eat within any two -hour period what most people 
would regard as an unusually large amount of food?  
              1  Yes     2  No  
IF NO: SKIP TO QUESTI ON 15  
 
11. During the times when you ate this way, did you often feel you couldn’t stop eating or control 
what or how much you were eating?  
              1  Yes     2  No  
IF NO: SKIP TO QUESTION 15  
 
12. During the past six months, how often, on average, did you have times when you ate this way 
– that is, large amounts of food plus the feeling that your eating was out of control? (There 
may have been some weeks when it was not present – just average those in). 
1. Less than one day a week  
2. One day a week  
3. Two or three days a week  
4. Four or five days a week  
5. Nearly every day  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
77/86 13. Did you usually have any of the following experiences during these occasions?  
a. Eating much more rapidly than usual?                                   Yes     No  
b. Eating until you felt uncomfortably full?                         Yes     No  
c. Eating large amounts of food when you didn’t feel physically hungry?  
                                                         Yes     No  
d. Eating alone because you were embarrassed by how much you were eating?  
                                                         Yes     No  
e. Feeling disgusted with yourself, depressed, or feeling very guilty after overeating?  
                                                                                             Yes     No  
 
14. Think about a typical time when you ate this way – that is, large amounts of food plus the 
feeling that your eating was out of control.  
a. What time of day did the episode start?  
1. Morning (8 am to 12 noon)  
2. Early afternoon (12 noon to 4 pm)  
3. Late afternoon (4 pm to 7 pm)  
4. Evening (7 pm to 10 pm)  
5. Night (after 10 pm)  
 
b. Approximately how long did this episode of eating last, from the time you started to eat 
to when you stopped an d didn’t eat again for at least  two hours  
              _____ hours ______ minutes  
 
c. As best you can remember, please list everything you might have eaten or drunk during 
that episode. If you ate for more than two hours, describe the foods eaten and liquids 
drunk during the two hours that you ate t he most. Be specific – include brand names 
where possible and amounts as best you can e stimate. (For example: 198 g  (7 oz) Ruffles 
potato chips; 1 cup Breyer’s chocolate ice cream with 2 teaspoons hot fudge; two 237 -mL 
(8-fl oz)  glasses of Coca -cola, 1½ ha m and cheese sandwiches with mustard).  
 
 
 
 
d. At the time this episode started, how long had it been since you had previously finished 
eating a meal or snack?  
              _____ hours ______ minutes  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
78/86 15. In general, during the past six months, how upset were you  by overeating (eating more than 
you think is best for you)?  
1. Not at all  
2. Slightly  
3. Moderately  
4. Greatly  
5. Extremely  
 
16. In general, during the past six months, how upset were you by the feeling that you couldn’t 
stop eating or control what or how much you were eating?  
1. Not at all  
2. Slightly  
3. Moderately  
4. Greatly  
5. Extremely  
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
79/86 27.2 Appendix 2: Food Habits  
 
QUESTIONNAIRE ON FOOD HABITS BEFORE TREATMENT  
Last Name _____________________  First Name ________________ M.I. ______  
Subject Number _ ________________  Date _______________________________  
________________________________________________________________________  
 
Thank you for completing this questionnaire. Please circle the appropriate letter . You may skip any 
question you do not wish to answer.  
 
1. Do you eat me at, like beef chicken or pork?  
a. Yes, every day or almost every day  
b. Yes, but not every day  
c. I hardly eat those foods  
d. I never eat those foods  
 
2. Are you a vegetarian or a vegan?  
a. I am a vegetarian  
b. I am a vegan  
c. I am not a vegetarian or a vegan  
 
3. Do you eat breakfas t? 
a. Yes, every day  
b. Yes, but not every day  
c. Only once or twice a week  
d. I almost never eat breakfast  
 
4. Which statement best describes your eating habits  regarding main meals ? 
a. I eat almost every day breakfast lunch and dinner  
b. I eat almost every day lunch and dinner but not breakfast  
c. I eat almost every day breakfast and lunch but not dinner  
d. I eat almost every day breakfast and dinner but not lunch  
e. I do not  eat regular meals and I eat when I am hungry  
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
80/86 5. Which statement best describes your eating habits  regardin g snacks ? 
a. I usually do not  eat much during the meals and I like to have  snacks during the day  
b. I eat most of my food during the meals but I also have three or more snacks during the  
day 
c. I eat most of my food during the meals and I have not more than two sna cks during the 
day 
d. I eat most of my food during the meals and I usually do not  have snacks during the day  
 
  
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
81/86 27.3 Appendix 3: Food Habits and Satisfaction  
 
QUESTIONNAIRE ON FOOD HABITS AND SATISFACTION AFTER 
TREATMENT  
Last Name _____________________  First Name ________________ M.I. ______  
Subject Number _ ________________  Date _______________________________  
________________________________________________________________________  
 
Thank you for completing this questionnaire. Please circle the appropriate letter or write in 
information where asked. You may skip any question you do not wish to answer.  
 
Food Habits  
1. Do you eat meat , like beef chicken or pork?  
a. Yes, every day or almost every day  
b. Yes, but not every day  
c. I hardly eat those foods  
d. I never eat those food s 
 
2. Are you a vegetarian or a vegan?  
a. I am a vegetarian  
b. I am a vegan  
c. I am not a vegetarian or a vegan  
 
3. Do you eat breakfast?  
a. Yes, every day  
b. Yes, but not every day  
c. Only once or twice a week  
d. I almost never eat breakfast  
 
4. Which statement best describes your eating habits  regarding main meals ? 
a. I eat almost every day breakfast lunch and dinner  
b. I eat almost every day lunch and dinner but not breakfast  
c. I eat almost every day breakfast and lunch but not dinner  
d. I eat almost every day breakfast and dinner but not l unch  
e. I do not  eat regular meals and I eat when I am hungry  
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
82/86 5. Which statement best describes your eating habits  regarding snacks ? 
a. I usually do not  eat much during the meals and I like to have  snacks during the day  
b. I eat most of my food during the meals but I also have three or more snacks during the  
day 
c. I eat most of my food during the meals and I have not more than two snacks during the 
day 
d. I eat most of my food during the meals and I usually do not  have snacks during the day  
 
 
Satisfaction  
1. Would you recommend these capsules to a relative or a  friend who wants to lose weight?  
a. Yes 
b. No 
 
2. On a scale of 1 to 10, how would you rate your experience  using these capsules? (10 
being very positive and 1 being very negative) ____  
 
Please explain why you gave this rating:  
________________________________________________________________________  
 
What did you like about the capsules?  
________________________________________________________________________  
 
What did you not like a bout the capsules?  
________________________________________________________________________  
 
3. Would you like to continue receiving these capsules?  
a. Yes 
b. No 
 
If No, please explain why:  
________________________________________________________________________  
 
4. If you were to continue taking the same amount of active product in this study, would 
you prefer to take smaller capsules but in a larger nu mber? (Please see the real examples 
before answering the question)  
a. Yes, I would prefer smaller capsules, but more of them (e.g., 4 or 5 capsules each time)  
b. No, I would prefer the current size capsules and continue with 3 capsules each time 
 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
83/86 27.4 Appendix 4: Impact of Weight on Quality of Life  
 
QUESTIONNAIRE ON IMPACT OF WEIGHT ON QUALITY OF LIFE  
(IWQOL)  
Last Name _____________________  First Name ________________ M.I. ______  
Subject Number _ ________________  Date _______________________________  
________________________________________ ______________________________ __ 
 
Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
84/86  

Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
85/86  

Protocol Number: G -04 (Version: 5.0; Version Date: August 24, 2016)  Gelesis, Srl.  
Product: Gelesis100  
______________________________________________________________________________  
Property of Gelesis, Srl. – Strictly Confidential  
 
86/86 27.5 Appendix 5: List of Source Data  
 
Subject’s identity  
Pathology studied, date of diagnosis  
Medical history, associated diseases (date of onset)  
Dates of administration of the study product  
Previous and concomitant medications  
A statement that the Informed Consent Form was signed by the subject  
Dates of participation in the study  
Dates of study visits  
Assessments performed during the study  (including questionnaires ) 
AEs and SAEs (and follow -up) 
Date of dropout (and reason)  
 